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The Role of SHP-1 in Deafferentation-induced Neuronal Death in The Murine 
A nditnrv  R rainstem
ABSTRACT
Deafferentation is the loss of sensory input from a portion of the body to the central 
nervous system (CNS), usually caused by interruption of the peripheral sensory fibers. 
Removal of afferent input, or changes in afferent activity, has been shown to have a 
dramatic impact on neuronal structure and function during a “critical period” of 
development in the auditory system. Inner ear cochlear ablation results in the death of 
anteroventral cochlear nucleus (AVCN) neurons from birth to approximately postnatal 
day 14 (PI4) in the murine auditory brainstem. However, the underlying physiological 
mechanisms that define the critical period of deafferentation-induced neuronal death are 
still incompletely understood. Glial cells, especially microglia, have received much 
attention as being important CNS immunoregulatory cells and active participators in the 
pathogenesis of neuron damage during injury, infection, and neurodegenerative diseases. 
Increasing evidence has suggested that once activated, microglia are capable of inducing 
neuronal death by secreting neurotoxic substances. Whether microglial activation helps 
determine the critical period for deafferentation-induced neuronal death in the auditory 
brainstem remains to be elucidated. Activation of glia often involves phosphorylation 
events controlled by the antagonistic actions of protein tyrosine kinases and protein 
tyrosine phosphatases. SHP-1 is a cytoplasmic protein tyrosine phosphatase 
predominantly expressed in hematopoietic cells and has been implicated as a negative 
regulator in cytokine signaling as well as in the proliferation and differentiation of 
various cell types, including glia. These studies utilize the SHP-1 deficient motheaten 
(me/me) mouse model to investigate the role of SHP-1 and activated microglia in 
deafferentation-induced AVCN neuronal death. In vivo studies demonstrate that 
following cochlear ablation 1) there is an extended critical period (beyond PI 4) of neuron 
loss concomitant with exaggerated microglial activation in the me/me AVCN; and 2) a 
down-regulated expression of the anti-inflammatory cytokines IL-4 and IL-10 in 
combination with an up-regulated expression of the pro-inflammatory cytokine IL-ip in 
the injured me/me hindbrain post-ablation. In vitro studies corroborate the deleterious 
role of activated me/me microglia in contributing to neuronal death by demonstrating an 
increased release of neurocytotoxic substances by cultured me/me microglial cells.
r \  I
Director: Diana I. Lurie, Ph.D.
l i
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
ACKNOWLEDGMENTS
I am greatly indebted to my advisor, Dr. Diana Lurie, who has not only offered 
unflagging guidance and support throughout the project, but has also patiently assisted 
me in improving my writing and English communication skills.
I would like to express my earnest appreciation to the members of my dissertation 
committee, Drs. Coffin, Holian, Lurie, Poulsen, Sugden, and Thompson, who have 
provided numerous invaluable suggestions over the course of this dissertation project.
Thank you to the faculty, staff and fellow graduate students of the Department of 
Biomedical & Pharmaceutical Sciences and the School of Pharmacy and Allied Health 
Sciences for providing resources, interaction and support to enhance my educational 
experience at the University of Montana.
Finally, my deep thanks to my family and faithful friends for their sustained 
encouragement and strong support that saw me through to the last phase.
iii
R eproduced  with perm ission o f the copyright owner. Further reproduction prohibited without perm ission.
TABLE OF CONTENTS
TITLE........................................................................................................................... i
ABSTRACT..................................................................................................................ii
ACKNOWLEDGMENTS.................................................................................. .......... iii
TABLE OF CONTENTS..............................................................................................iv
LIST OF TABLES...................................................................................... ................. v
LIST OF FIGURES.......................................................................................................vi
INTRODUCTION........................................................................................................ 1
CHAPTER ONE...........................................................................................................16
CHAPTER TWO......................... ........... ......................................................................58
CHAPTER THREE....................................................................................................... 86
CONCLUSIONS...........................................................................................................119
iv
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
LIST OF TABLES
Table 1 Quantification of F4/80 immunoreactivity.............................................. 28
Table 2 Neuron number in AVCN 4 days post-ablation...................................... 39
Table 3 Quantification of GFAP immunoreactivity............................................. 46
v
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
LIST OF FIGURES
Figure 1 F4/80 immunoreactivity in AVCN following deafferentation..............26
Figure 2 F4/80+ microglia in P14 wild-type vs. me/me AVCN..........................29
Figure 3 Time course of microglial activation in P5 & P14 AVCN  ......32
Figure 4 H&E staining of neurons in P5 & P14 AVCN............... ........ ............35
Figure 5 Percent AVCN neuron loss after cochlear ablation ..................37
Figure 6 GFAP immunoreactivity in AVCN following deafferentation..............42
Figure 7 GFAP+ astrocytes in P14 wild-type vs. me/me AVCN  ............44
Figure 8 Time course of astrocyte activation in P5 & P14 AVCN  ............ 47
Figure 9 Cytokine profile in the intact hindbrain............................................... ..67
Figure 10 Decreased IL-4 & IL-10 inthe injured me/me hindbrain....................... 70
Figure 11 Increased IL-ip in the injured me/me hindbrain.............. .................... 73
Figure 12 Expressions of TNF-a & EFN-y following deafferentation...................75
Figure 13 Nitric oxide release from wild-type vs. me/me microglia. ................ 96
Figure 14 TNF-a production by wild-type vs. me/me microglia............. ..............99
Figure 15 IL-lp secretion from wild-type vs. me/me microglia  ....................102
Figure 16 LPS-induced ERK phosphorylation in microglia................   105
Figure 17 LPS-induced p38 MAPK phosphorylation in microglia. .................... 107
vi
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
INTRODUCTION
Loss or impairment of peripheral sensory input from a portion of the body to the 
central nervous system (CNS) is referred to as deafferentation. Removal of presynaptic 
afferent input or changes in afferent activity have been shown to have a striking impact 
on the structure and function of postsynaptic neurons during a “critical period” of 
development in a number of different systems (Hubei and Wiesel, 1970; Lasiter and 
Kachele, 1990; Brunjes, 1994; Baldi et al., 2000; Mostafapour et al., 2000). In the 
auditory system, loss of hair cells, the peripheral auditory receptors, by either mechanical 
lesions of the cochlea or biochemical lesions of the hair cells by ototoxic drugs, can 
profoundly influence the morphology, functional performance and survival of developing 
cochlear nucleus (CN) neurons in the central auditory system. Although the effect of 
changes in neural input during these critical periods has been well characterized, the 
underlying biological and physiological mechanisms remain to be fully elucidated.
Changes in Auditory Brainstem Neurons following Deafferentation
The auditory brainstem of birds and mammals is an excellent model in which to 
study the effects of afferent deprivation and the biological basis of the critical period. 
Neurons within the chicken cochlear nucleus n. Magnocellularis (NM) receive a single 
excitatory input from the eighth cranial nerve. When this afferent activity is removed, 
25-30% of NM neurons die within the first few days of activity loss (Bom and Rubel, 
1985; Bom and Rubel, 1988; Bom et al., 1991). Some of the early changes that occur in 
NM neurons in response to deafferentation include decreases in transcription and protein
1
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synthesis (Steward and Rubel, 1985; Garden et al., 1994; Kelley et al., 1997) and 
increases in intracellular calcium (Zirpel et al., 1995; Zirpel and Rubel, 1996). The latter 
is thought to activate the transcription factor calcium/cAMP response element-binding 
protein (CREB) (Zirpel et al., 2000), and CREB phosphorylation has been shown to be 
important for neuronal survival in a variety of different cells (Hu et al., 1999; Walton et 
al., 1999; Walton and Dragunow, 2000). In contrast, neurons that are destined to die 
following deafferentation show polyribosomal degradation among various other 
intracellular changes (Garden et al., 1994; Hartlage-Rubsamen and Rubel, 1996).
Unlike birds, the switch from afferent-dependent to afferent-independent neuronal 
survival in the CN of the mammalian auditory brainstem is temporally related to hearing 
onset. Recent work has indicated that in both gerbil and mouse, there is an extremely 
narrow window during which CN neurons are susceptible to deafferentation-induced cell 
death (Tierney et al., 1997; Mostafapour et al., 2000). Cochlear removal at or before P7 
results in 50-80% neuron loss within the cochlear nucleus, while at P9-14 or later, no 
significant neuronal death occurs.
Synaptic maturation during development may play a key role in defining this 
critical period of neuronal susceptibility within the mammalian auditory system. 
However, other intrinsic biological properties of neurons also appear to be important. 
Bcl-2 has been shown to be an effector of cell survival as AVCN neurons switch from 
afferent-dependent to afferent-independent mechanisms because bcl-2 knockout mice 
remain susceptible to death following cochlear removal through P21 (Mostafapour et al.,
2000) and bcl-2 overexpression eliminates neuronal death within AVCN in very young 
mice (Mostafapour et al., 2002). Another apoptotic mediator, caspase-3 has also been
2
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implicated in the cell death pathways of CN neurons following cochlear ablation 
(Mostafapour et al., 2000). It has become increasingly clear that a complex series of 
events determines whether a neuron will live or die following deafferentation. Among 
these, the role of glial cells should not be overlooked since interactive communications 
between neurons and glia exist, particularly in response to injury.
Glial Response to afferent injury o f the auditory brainstem
Besides neural injury, CNS lesion also leads to a cascade of events resulting in 
glial activation (Kreutzberg et al., 1989). Two major types of glia, astrocytes and 
microglia, play an important role in the repair of injured tissue and these cells have been 
shown to respond to injury in ways that are both supportive and inhibitory of neuronal 
survival and regeneration. In particular, in response to injury, quiescent astrocytes 
become hyperplastic and hypertrophied, proliferating to fill the space left by degenerating 
neurons (Reier and Houle, 1988). Microglia, considered to be the immune cells of the 
brain, are also extremely sensitive to CNS damage (Gehrmann et al., 1995; Hanisch,
2002) and act as phagocytes (Aldskogius and Kozlova, 1998). The microglial response 
to injury is often characterized as a “double-edged sword” depending on the magnitude of 
the reaction and the type of stimulus; microglia can either contribute to host defense and 
repair, or intensify the CNS damage.
Cochlear removal in the avian results in astrocyte proliferation and hypertrophy 
within the deafferented brainstem nucleus NM (Canady and Rubel, 1992; Rubel and 
MacDonald, 1992; Lurie and Rubel, 1994). Previous studies in our laboratory have
3
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found that immunoreactivity for the protein tyrosine phosphatase SHP-1 increases in a 
subset of astrocytes following cochlear removal in chicken and these SHP-1+ astrocytes 
do not appear to enter the cell cycle (Lurie et al., 2000). This suggests that SHP-1 
negatively regulates astrocytic cell division. Later studies in vitro also support this 
hypothesis. Addition of the protein tyrosine phosphatase inhibitor sodium orthovanadate 
(Na3VC>4) to mixed neural/glial cultures of the avian brainstem results in a dose- 
dependent increase in astrocyte proliferation (Sorbel et al., 2002).
To date, no studies have documented the microglial response in the auditory 
brainstem following cochlear removal in either avian or mammalian models. However, 
other types of afferent injury such as axotomy of peripheral facial nerves, leads to a 
massive upregulation of SHP-1 in activated microglia and astrocytes (Horvat et al.,
2001). Moreover, deafferentation by axonal interruption of motomeurons results in 
microglial proliferation and expression of new proteins such as vimentin or major 
histocompatibility complex (MHC) antigens (Kreutzberg et al., 1989), which may 
subsequently elicit immune functions of microglia.
Microglia And CNS Immunoregulation after Injury
Although the main function of microglia is to serve as immune surveillance for 
the CNS, they have increasingly received more attention as their activation and/or 
dysregulation is involved in most neurological disorders (Aloisi, 2001; Nelson et al., 
2002; Schwartz, 2003). One of the most remarkable properties of microglia is their 
ability to respond to endogenous or exogenous signals and become activated for the
4
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purposes of tissue repair or the induction of immune responses (Aloisi, 2001).
Expression of a large array of surface receptors on microglia, including pattern 
recognition receptors, complement receptors, cytokine/chemokine receptors, etc., enables 
these cells to exert their immunoregulating functions in response to a variety of infectious 
and inflammatory stimuli (Aloisi, 2001). Significantly, microglia are thought to be both a 
source and target of immunoregulatory cytokines (Hanisch, 2002), and many of these 
immune mediators are involved in the initiation of different signaling pathways that could 
lead to glial activation and neural/glial damage. Microglial-induced synthesis of 
cytokines (such as the anti-inflammatory cytokines IL-10, IL-1 receptor antagonist and 
TGF-P, as well as the pro-inflammatory cytokines IL-1, IL-6, IL-12 and TNF-a) has 
been demonstrated in vivo and in vitro as a response to trauma and infection or as a 
hallmark of neuropathological changes (Hanisch, 2002). The complex cytokine network 
that controls the CNS immune system can be disturbed and augmented by CNS injury, 
which may in turn potentiate microglial activation resulting in a deleterious interaction 
between neurons and glia.
Microglial Induction o f Neuronal Death
Accumulating evidence suggests that activated microglia can induce neurons to 
die both in vivo and in vitro through a variety of mechanisms. It has been suggested that 
the release of reactive oxygen species nitric oxide (NO) (Loihl and Murphy, 1998; 
Liberatore et al., 1999; Bal-Price and Brown, 2001), pro-inflammatory cytokines TNF-a 
and IL-lp (Chao et al., 1995; Viviani et al., 1998) and the excitatory amino acid
5
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glutamate (Barger and Basile, 2001) by activated microglia all contribute to neuronal 
death following injury and disease. In particular, the release of iNOS (inducible nitric 
oxide synthase)-derived NO is thought to inhibit neuronal respiration, causing glutamate 
release, and the subsequent excitotoxic death of neurons (Bal-Price and Brown, 2001). In 
addition, activated microglia themselves secrete glutamate (Barger and Basile, 2001) and 
may also induce glutamate release from astrocytes via NO induction (Bal-Price and 
Brown, 2001). Activated microglia show increased induction of iNOS and TNF-a 
through activation.of the extracellular signal-regulated kinase (ERK) and p38 MAP 
kinase subgroups of MAP kinase (MAPK) (Bhat et al., 1998). Inhibition of microglial 
activation and proliferation by the tetracycline derivative, minocycline, results in 
increased neuronal survival in neural/glial cultures of rat brain via inhibition of NO and 
IL-ip release (Tikka et al., 2001). In vivo studies also suggest that microglial activation 
in the parkinsonian substantia nigra can be inhibited by minocycline treatment and a large 
number of nigral neurons rescued from degeneration (He et al., 2001).
It is not known whether there is microglial activation in response to cochlear 
removal in the auditory brainstem, nor whether such activation could contribute to 
deafferentation-induced cell death or the timing of the critical period. Since SHP-1 
immunoreactivity is also upregulated in microglia after deafferentation (Kreutzberg et al., 
1989; Horvat et al., 2001; Wishcamper et al., 2003), SHP-1 could be a component of the 
signaling pathways involved in the modulation of microglial activation following injury. 
Significantly, SHP-1 has been shown to limit ERK activity (Shibasaki et al., 2001) and 
may be indirectly involved in the down-regulation of p38 MAP kinase (Kumar et al.,
6
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1999). This raises the possibility that SHP-1 could negatively regulate microglial 
activation and influence microglia-induced neuronal death.
The Protein Tyrosine Phosphatase SHP-1
SHP-1 (also known as PTP1C, SHPTP-1, and SHP) is a cytoplasmic protein 
tyrosine phosphatase containing two src homology 2 (SH2) domains. It was first isolated 
from human breast cancer cells (Shen et al., 1991) and has been most thoroughly 
characterized in hematopoietic cells, where it is expressed at high levels and plays 
important physiological roles (Plutzky et al., 1992; Yi et al., 1993; David et al., 1995; 
Krautwald et al., 1996). In the CNS, SHP-1 is involved in neuronal differentiation 
(Mizuno et al., 1997) and somatostatin receptor sst2 growth inhibitory signaling via direct 
action on neuronal nitric oxide synthase (nNOS) (Lopez et al., 2001). Moreover, SHP-1 
is thought to modulate cytokine activity by limiting activation through the erythropoietin 
(Epo), interleukin 3 (IL-3) and type I interferon (IFN) receptor pathways by binding to 
and dephosphorylating JAK (Janus kinase) and STAT (signal transducers and activators 
of transcription) proteins (Massa and Wu, 1996) and by controlling expression oflFN- 
inducible genes of the transcription factor NF-kB in astrocytes (Massa and Wu, 1998).
Motheaten (me/me) Mice
The animal model used in the present studies to examine neural/glial interactions 
and glial factors contributing to neuronal death in the auditory brainstem following 
afferent injury is a mouse mutant that lacks functional SHP-1 protein, called motheaten
7
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(me/me) mice. This mutation disrupts the SHP-1 gene on mouse chromosome 6 and is 
caused by a deletion of a cytidine residue which generates a frameshift and premature 
truncation of SHP-1 mRNA such that me/me mice are effectively null for SHP-1 protein 
(Kozlowski et al., 1993; Shultz et al., 1993; Tsui et al., 1993). Loss of SHP-1 leads to 
many hematopoietic abnormalities including an overproduction of macrophages and 
neutrophils (Shultz et al., 1984), a severe reduction in the number of early B cell 
progenitors (Schweitzer and Shultz, 1988; Shultz, 1988) and abnormal mast cell 
development (Shultz et al., 1997). The mutation confers an easily recognizable 
phenotype characterized by patchy dermatitis, reduced body size and weight, progressive 
arthritis, limb necrosis, and hemorrhagic pneumonitis, the latter of which is the primary 
cause of death (Shultz et al., 1993). The me/me mice die at a mean age of 3 weeks due to 
intra-alveolar hemorrhage as a consequence of infiltration of macrophages and 
neutrophils (Shultz et al., 1984). However, these animals remain healthy and viable up 
until a few days before death.
8
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SPECIFIC AIMS
Specific Aim I.
Specific Aim II.
Specific Aim III.
Precisely define the temporal relationship between neuronal 
susceptibility and glial activation following afferent injury
-  Quantify the time course and magnitude o f the neuronal, 
astrocyte and microglial response within AVCNfollowing cochlear 
ablation in wild-type and me/me mice
Determine the role of SHP-1 in regulating inflammatory mediators 
involved in deafferentation-induced brain injury
—Establish the pro- and anti-inflammatory cytokine 
profiles o f wild-type and me/me brains before and after 
deafferentation
Ascertain whether loss of SHP-1 alters the function of activated 
microglia implicated in inducing neurotoxicity
-Identify whether activated me/me microglia release 
increased amounts o f the neurotoxic substances nitric oxide (NO), 
tumor necrosis factor-a (TNF-a) and Interleukin-1 p  (IL-1P) 
compared to wild-type microglia in vitro
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CHAPTER ONE
Cochlear ablation in mice lacking SHP-1 results in an extended period of cell 
death of anteroventral cochlear nucleus neurons
Abstract
Cochlear ablation results in the death of anteroventral cochlear nucleus (AVCN) 
neurons from birth to approximately postnatal day 14 (P14) in the murine brainstem. It is 
not known whether microglial activation contributes to AVCN neuronal death following 
deafferentation. In order to determine whether microglial activation helps to define the 
period of neuronal susceptibility within AVCN, we performed unilateral cochlear 
ablation on mice lacking the protein tyrosine phosphatase SHP-1' (me/me). These mice 
have been shown to have an exaggerated microglial response following ischemic injury. 
In the present study, the glial and neuronal response to deafferentation within AVCN was 
examined in wild-type and me/me mice at P5, P I4, and P21. Lack of SHP-1 results in 
robust microglial but not astrocyte activation within the ablated P14 me/me AVCN.
These mice also exhibit approximately 28% neuronal death at P14, a time when normal 
wild-type littermate controls show little cell death. Glial activation and neuronal loss at 
P5 and P21 were similar between the two phenotypes, suggesting a role of activated 
microglia in inducing neuronal death beyond P14 but not P21. These results indicate that 
activated microglia may participate in determining whether neurons in AVCN live or die 
following deafferentation.
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1. Introduction
Removal of afferent input or changes in afferent activity have been shown to have 
a dramatic impact on the development of mature neuronal structure and function during a 
“critical period” of development in a number of different systems (Hubei and Wiesel, 
1970; Brunjes, 1994; Mostafapour et al., 2000). Within the auditory system, the 
sensitivity of cochlear nucleus neurons to removal of afferent input decreases over time. 
Bom and Rubel (1985) first described this change from afferent-dependent to afferent- 
independent survival in the avian cochlear nucleus and studies in mammals have 
suggested that this transition to afferent-independent survival is temporally related to 
hearing onset within the auditory brainstem (Trane, 1982; Nordeen et al., 1983; Webster, 
1983; Webster, 1988; Hashisaki and Rubel, 1989; Kitzes et al., 1995). Recent work has 
indicated that in both the gerbil and the mouse, there is an extremely narrow window 
during which the anteroventral cochlear nucleus (AVCN) neurons are susceptible to 
deafferentation-induced cell death (Tiemey et al., 1997; Mostafapour et al., 2000). 
Cochlear removal at or before postnatal day 7 (P7) results in 50-88% neuron loss within 
the mammalian cochlear nucleus, while the same procedure performed atP14 or later 
results in no significant cell death.
Although the effect of changes in neural input during this critical period has been 
well characterized, the underlying physiological mechanisms that define critical periods 
are not well understood. Within AVCN, the transition from afferent-dependent to 
afferent-independent neuronal survival is thought to be largely regulated by the intrinsic 
properties of neurons including the apoptotic mediators Bcl-2 and caspase-3
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(Mostafapour et al., 2000; Mostafapour et al., 2002). However, little attention has focused 
on the role that glial cells may play in defining critical periods. Accumulating evidence 
suggests that activated microglia can kill neurons by secreting neurotoxic substances such 
as nitric oxide, TNF-a and/or glutamate in several CNS disorders including 
inflammatory, infectious, traumatic, and neurodegenerative diseases (Bhat et al., 1998; 
Bal-Price and Brown, 2001). Collectively, these results suggest that activated microglia 
could induce death in a population of neurons that have been weakened by 
deafferentation, but might otherwise survive the deafferentation injury.
Previous studies in our laboratory have demonstrated that the protein tyrosine 
phosphatase SHP-1 is upregulated in glial cells following injury (Wishcamper et al.,
2003). Importantly, mice lacking SHP-1 (motheaten) have an exaggerated microglial 
response following ischemic injury to the brain (Wishcamper, Brooks, and Lurie,
Personal Observation). SHP-1 has been implicated as a negative regulator in a number of 
different signaling pathways including the direct modulation of the JAK/STAT pathway 
(Finbloom and Lamer, 1995; Bousquet et al., 1999; Hilton, 1999; Starr and Hilton, 1999) 
and indirect modulation of ERK and p38 MAP kinases (Kumar et al., 1999; Shibasaki et 
al., 2001). Both the ERK and p38 MAP kinase signaling cascades are involved in 
microglial activation (Bhat et al., 1998) and activated microglia may play a role in 
determining whether neurons live or die following deafferentation.
In the present study, glial activation and neuronal cell loss within the auditory 
brainstem in response to cochlear ablation is compared between motheaten mice and 
wild-type controls in order to evaluate whether the microglial response plays a role in 
determining neuronal survival within AVCN following deafferentation. P5, P14, and P21
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me/me and wild-type mice received a unilateral cochlear ablation and were allowed to 
survive for 2,4 or 6 days. Microglial and astrocyte activation, and neuronal cell loss, 
were examined within AVCN at 4 days after injury. Confirming the results of previous 
studies (Mostafapour et al., 2000), there is approximately 50% neuronal cell loss within 
the P5 AVCN 4 days following cochlear ablation in wild-type as well as me/me mice. 
However, in contrast to their normal littermates, motheaten mice continue to demonstrate 
significant amounts of deafferentation-induced neuronal death at P14, although by P21, 
there is no difference in neuronal loss between wild-type and me/me mice. Importantly, 
there is increased microglial activation following deafferentation in P14 me/me mice 
compared to wild-type, and this microglial activation may induce death in AVCN 
neurons that would otherwise survive following deafferentation at this time point. These 
findings suggest that activated microglia play a role in determining the critical period of 
neuronal susceptibility following cochlear ablation in the murine auditory brainstem.
2. Materials and methods
2.1. Animals
The founding mice (C3FeLe.B6-a/a-Hcphme/+) were obtained from The Jackson 
Laboratory (Bar Harbor, ME). Mice used in this study were propagated by +/me matings, 
producing me/me mutants, and +/+ and +/me wild-type control littermates. Mice were 
maintained in microisolator units and kept in the University of Montana specific 
pathogen free (SPF) animal facility. Mice were given free access to food and water and
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were placed in a 12-hour light/dark cycle, constant temperature and humid environment. 
All animal procedures were in strict accordance with the NIH Guide for the Care and 
Use o f Laboratory Animals and were approved by the University of Montana Institutional 
Animal Care and Use Committee.
2.2. Mouse Genotyping
Polymerase chain reaction (PCR) amplifying a 426-bp fragment, which 
encompasses the site of the me/me mutation, was utilized to genotype the mice. The PCR 
reaction was carried out using forward (5'-CGCTGCTGCTCATGTATCTC-3') and 
reverse (5'-GCCTACAGAGGGAAGAGGCT-3') primers (Operon Technologies, 
Alameda, CA) and the PCR Master Mix (Promega Corporation, Madison, WI). At 
weaning, 2-3 mm tail samples were digested in 100 mM NaOH at 65°C for 3 hours. 
Digestion was terminated by adding 0.75 M Tris-HCl (pH 7.5) prior to centrifugation. 
DNA was subjected to 35 cycles of the following PCR conditions: 30 seconds at 95°C, 1 
minute at 56°C, and 1 minute at 72°C. The amplified PCR products were digested for 1 
hour with 1.0 pi Taq I enzyme (New England BioLabs, Beverly, MA) at 65°C and 
separated by 1.2% agarose gel electrophoresis in 1 x TAE at 120 V for 100 minutes. PCR 
products were stained with ethidium bromide and visualized by UV light.
2.3. Unilateral Cochlear Ablation
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P5, P14, and P21 (n = 4-5/age group) mice were anesthetized with 2,2,2- 
tribromoethanol (375 mg/kg, i.p.) and received a unilateral cochlear ablation. A separate 
group of both wild-type and motheaten P21 control mice (n = 3) were anesthetized and 
allowed to recover. Surgeries were performed as previously described with some 
modifications (Mostafapour et al., 2000). Briefly, for P5 animals whose ear canals have 
not developed, a horizontal incision was made 2-3 mm inferior to the pinna of the right 
ear using fine surgical scissors. The middle ear mesenchyme was cut and the ossicles 
were removed, exposing the basal turn of the cochlea. Using a 27-gauge needle with a 
blunt tip connected to a vacuum pump, the bony wall of the cochlea was penetrated and 
the contents aspirated. The skin incision was closed with cyanoacrylic glue. For animals 
P14 and older, the right ear pinna inferior region was shaved and an incision was made 
on the inferior side of the pinna. The ear canal was enlarged by making further incision at 
its entry, and the tympanic membrane was punctured and the ossicles were removed 
using a pair of fine forceps. The basal turn of the cochlea was visualized and destroyed 
with a 27-gauge needle followed by aspiration of its contents. The incision was closed 
with cyanoacrylic glue. All surgical procedures were performed on a warming pad and 
animals were given oxygen inhalation after surgery on a heating element until they were 
fully awake. Following the unilateral cochlea ablation, mice were allowed to survive for
2.4, or 6 days. Non-surgical controls were sacrificed 4 days following anesthesia.
2.4. Immunohistochemistry
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Immunohistochemistry was performed as previously described (Lurie and 
Durham, 2000; Lurie et al., 2000). At 2,4, or 6 days after cochlear ablation, mice were 
deeply anesthetized with tribromoethanol and transcardially perfused with phosphate- 
buffered saline (PBS) for 10 minutes followed by 10 minutes with 4% Na-periodate- 
lysme-paraformaldehyde (PLP) fixative. Brains were removed and post-fixed in PLP 
fixative at 4°C for an additional 24 hours. The tissue were then rinsed several times in 
PBS over a 4-6 hour period and placed in a Shandon Citadel™ tissue processor (Shandon 
Scientific Limited, Runcorn, Cheshire, England) to be dehydrated in increasing ethanol 
(70%, 95%, and then 100%) and embedded in paraffin. Ten-micron thick coronal 
sections of the brainstem containing the AVCN were cut and collected, and a 1 in 6 series 
mounted onto Superfrost plus micro slides (VWR Scientific, West Chester, PA). The first 
series of tissue sections were stained with either thionin or hematoxylin and eosin 
(Shandon, Pittsburgh, PA) to identify neurons. Subsequent series were processed for the 
appropriate antibodies using the avidin-biotin-peroxidase complex (ABC) method with 
reagents from Vectastain kits (Vector Laboratories, Burlingame, CA) as previously 
described (Lurie et al., 2000). Briefly, sections were deparaffinized, rinsed in 0.1 M Tris 
buffer (pH 7.4) and then blocked with 4% normal goat serum (for polyclonal antibodies) 
or 4% normal horse semm (for monoclonal antibodies) for 20 minutes. This and all other 
immunohistochemistiy reagents (except for ABC reagent) were prepared in 0.5% bovine 
serum albumin (BSA)/0.1% sodium azide in Tris buffer. Sections were incubated 
overnight in anti-glial fibrillary acidic protein (GFAP; polyclonal, 1: 2000; Dako, 
Carpinteria, CA) or for 2 days in anti-F4/80 (monoclonal, 1:75; Serotec, Raleigh, NC) at 
4°C in a humidified chamber. Sections were then washed in Tris, incubated in
22
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biotinylated goat anti-rabbit or horse anti-mouse serum (Vector Laboratories) at 1:400 in 
the humidified chamber for 1 hour, washed in Tris, then incubated in the avidin-biotin 
complex (Vectastain ABC Elite kit, Vector Laboratories) for 1 hour. The chromogen used 
was diaminobenzidine (0.25 mg/ml; Sigma, St. Louis, MO) prepared with 0.1 M 
imidazole and 30% hydrogen peroxide in Tris buffer. Sections were then rinsed in water, 
dehydrated, and coverslipped with DPX (BDH Laboratory Supplies, Poole, England).
2.5. Image Analysis and Statistics
All slides were coded and analysis of tissue sections was performed by an 
individual blinded as to phenotype. Every stained tissue section from the 1 in 6 series was 
examined using standard light microscopy with a Nikon Eclipse E800 microscope. 
Thionin or hematoxylin and eosin staining was used to determine the borders of AVCN. 
The boundary between the AVCN and the posteroventral cochlear nucleus (PVCN) was 
defined by the appearance of the granular layer of the cochlear nucleus (GrC).
Image analysis for GFAP and F4/80 antibody immunostained sections was 
performed with the NIH Image Analysis V1.61 software as previously described 
(Wishcamper et al., 2001). A Powermac 8600/200 computer connected to a Nikon E800 
microscope by a Cohu black & white video camera was used. Sections chosen from the 
rostral, middle, and caudal portions of AVCN on both the ablated and uninjured sides 
were analyzed for staining density. The boundary of AVCN was outlined and a fixed 
threshold was set. The sum of the stained area (pm2), which reached the threshold within
fy
the outlined region, was divided by the sum of the entire AVCN area (pm ) from the
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three representative sections, and the ratio of staining within each side of the brainstem 
was obtained.
Neuron counts were performed using a 40 x objective and images were captured 
with a Nikon digital camera DXM1200 connected to a CG computer. All normal 
appearing neurons within AVCN in a given section were counted on both the ipsilateral 
and contralateral sides of the brainstem. The criteria for a neuron to be counted were a 
well-defined cytoplasm and nuclear membrane and clear nucleoli within the nucleus. The 
total AVCN neuron number in each side of the brainstem was defined as: Total number 
of neurons per side = sum of No. of neurons in all counted sections x 6. The contralateral 
AVCN was used as a within-animal control. Percentage of AVCN neuron loss on the 
injured side was calculated as: 100 x [(Total No. of neurons on control side -  Total No. 
of neurons on ablated side)/Total No. of neurons on control side]. “Double counting” was 
not considered because the nucleolus is small compared to section thickness 
(Mostafapour et al., 2000).
Statistical analysis was performed using the non-parametric Mann-Whitney U-test. 
The data are presented as the mean ± standard error of the mean (SEM), p < 0.05 was 
considered significant.
2.6. Photography
Digital images were captured with a Nikon E800 microscope attached to a Cohu 
black & white video camera by NIH Image Analysis V1.61 software on a Powermac
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8600/200 computer. Captured images were processed with Adobe Photoshop 5.5 to 
provide consistent size; and text, magnification bars and arrows were added.
3. Results
3.1. Microglial activation following deafferentation is upregulated in me/me mice
To elucidate the role of SHP-1 following deafferentation, the neuronal and glial 
response to cochlear ablation was examined in mice lacking functional SHP-1 (me/me).
A unilateral cochlear ablation was performed at P5, P14, and P21 in me/me and wild-type 
littermates. Animals were allowed to recover for 4 days and the AVCN was examined 
for neuronal loss and glial activation. Microglial activation was quantified by 
immunolabeling with the F4/80 antibody which labels activated microglia, and astrocyte 
activation was quantified using an antibody against GFAP. Neurons were counted within 
the deafferented AVCN and compared to the uninjured side to determine neuronal loss 
following cochlear ablation.
At P5, microglial activation increases two-fold in both the wild-type and me/me 
deafferented AVCN compared to the unablated side (Fig. 1) and is not significantly 
different between the two phenotypes (Fig. 1 and Table 1). However, me/me mice at P14 
display a very prominent, significant increase in microglial activation within the 
deafferented AVCN compared to age-matched wild-type mice (Fig. 2 A-D). Although, 
some microglial activation following deafferentation does occur in P14 wild-type mice,
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Figure 1: Percent of F4/80 immunoreactivity within the control and ablated sides of 
AVCN in wild-type and me/me mice after deafferentation. At P5, there is a similar but 
not significant increase in density of F4/80 immunostaining in the ablated side compared 
to the control side of AVCN in both me/me (3.8 ± 0.9% vs. 2.1 + 0.5%; n = 4) and wild- 
type littermates (3.7 ± 1.1% vs. 1.6 ± 0.3%; n = 4). When cochlear ablation is performed 
at PI4, me/me mice demonstrate a significant upregulation of F4/80 immunoreactivity in 
the ablated AVCN compared to the ablated wild-type AVCN (5.0 ± 1.2% vs. 2.2 ± 0.7%; 
n = 4; p < 0.05). In older animals at P21, there is a higher density of F4/80 staining in 
both the control and ablated AVCN in me/me mice compared to wild-type. Note that the 
basal level of F4/80 immunoreactivity in me/me mice on the control side (2.6 ± 1.4%) is 
significantly higher than that in wild-type mice (0.2 + 0.06%). Wt-ctr, wild-type control 
side; wt-abl, wild-type ablated side; me-ctr, me/me control side; me-abl, me/me ablated 
side. Error bars indicate standard error of the mean. Asterisk, Mann-Whitney U-test, p < 
0.05.
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Table 1. Quantification of F4/80 immunoreactivity
Age at 
surgery Phenotype n
Percent of F4/80 staining (mean ± SEM)
Control Ablated
P5
Wild-type
Me/me
4
4
1.56 + 0.29 
2.08 ±0.51
3.66 ± 1.06 
3.81 ±0.89
P14
Wild-type 4 
Me/me
1.09 ±0.18 
1.81 ±0.51
2.20 ± 0.66 
5.01 ± 1.19 *
P21
Wild-type
Me/me
4
5
0.19 ±0.06 
2.57 ± 1.39*
2.09 ± 0.72 
3.65 ±1.14
Table 1. Percent of AVCN immunopositive for F4/80 staining in wild-type vs. 
motheaten mice 4 days following cochlear ablation. The percent AVCN immunopositive 
for F4/80 staining was obtained by dividing the sum of the stained area (pm ) that 
reached threshold within AVCN by the sum of the area of AVCN (pm2) from three 
representative sections. Comparisons are made between age-matched wild-type and 
me/me mice. *Mann-Whitney U-test, p < 0.05.
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Figure 2. F4/80+ microglia in P14 wild-type vs. me/me AVCN
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Figure 2: F4/80 immunostaining in AVCN of wild-type vs. motheaten mice at P14,4 
days following cochlear ablation. Wild-type AVCN shows small numbers of F4/80+ 
microglia within the control side (A) and a small increase in the ablated side (B),
(arrows). However, there is a higher basal level of F4/80+ microglia in the control side of 
the me/me AVCN (C), and a significantly upregulated expression on the ablated side (D), 
(arrows). Notice that me/me microglia are transformed from the ramified, inactivated 
state (C), (arrow heads), to the amoeboid, activated state (D), (arrow heads), after 
cochlear ablation. Scale bar = 20 pm.
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quantification of the F4/80 immunoreactivity reveals that the deafferented me/me AVCN 
contains twice as much F4/80 immunolabeling compared to the deafferented wild-type 
AVCN at this age (Fig. 1 and Table 1). In addition to increased F4/80 expression, me/me 
microglial cells at P14 appear to transform from the ramified, resting state observed in 
the uninjured AVCN (Fig. 2C) to the amoeboid, activated state found in the deafferented 
AVCN (Fig. 2D). In contrast to the me/me mice, far fewer amoeboid-like microglia are 
seen within the deafferented wild-type AVCN (Fig. 2B)
At P21, the microglial response to deafferentation in wild-type mice is similar to 
that observed at P14 in wild-type mice (Fig. 1 and Table 1). In contrast, P21 me/me mice 
demonstrate less F4/80 immunostaining within the deafferented AVCN compared to 
me/me P14 animals although there is still an increased microglial response in the injured 
P21 me/me AVCN compared to the control side.
To determine whether loss of SHP-1 results in an increase in the magnitude of 
microglial activation versus an earlier peak response, P5 and P14 wild-type and me/me 
mice received a unilateral cochlear ablation and were allowed to survive for 2,4 or 6 
days. The brains were then processed for F4/80 immunohistochemistry. At P5, 
microglial activation is similar in wild-type and me/me mice within the ablated AVCN at 
all time points following cochlear ablation. As shown in Figure 3 A, both the time course 
and the magnitude of the microglial response is similar in both phenotypes with maximal 
activation occurring at 6 days following deafferentation. However, at P14, motheaten 
mice have significantly higher levels of microglial activation 4 days after cochlear 
ablation compared to wild-type (Fig. 3B). Day 4 after cochlear ablation appears to be an
31
R eproduced with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
Pe
rc
en
t 
of 
A
V
CN
 
Im
m
un
op
os
iti
ve
 
fo
r 
F4
/8
0
Figure 3. Time course of microglial activation in P5 & P14 AVCN
P5 F4/80 Time Course B P14 F4/80 Time Course
wt16 
14 
■ §  12 
55 10■a „ «> 8
I  6
1 4
” 2 
0
-  me
2 (n=3) 4 (n=4) 6 (n=3)
ooo
zu
<c ■oo ~ ® 
^ « i 5  
< 5 0 5
a. § -  
E 
E
wt16
14
12
10
8
6
4
2
0
-  me
6 (n=3)2 (n=3) 4 (n=4)
Time After Cochlear Ablation (Days) Time After Cochlear Ablation (Days)
32
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
Figure 3: Time course of F4/80 immunoreactivity at 2,4, and 6 days following cochlear 
ablation in the deafferented AVCN of P5 and P14 wild-type and me/me mice. A. Both 
the time course and magnitude of the F4/80 immunolabeling are similar in P5 wild-type 
and me/me mice. B. P14 me/me display a significantly higher level of F4/80 
immunoreactivity compared to the wild-type at 4 days following cochlear ablation (5 ±
1.2% vs. 2.2 ± 0.7%, n =4; p < 0.05), but similar F4/80 staining is observed at 2 and 6 
days in animals of both phenotypes. Error bars indicate standard error of the mean. 
Asterisk, Mann-Whitney {/-test, p < 0.05.
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important time point at P14 because the microglial response is similar between me/me 
and wild-type mice at days 2 and day 6 following deafferentation (Fig. 3B).
3.2. Me/me mice lacking SHP-1 are more vulnerable to deajferentation-induced 
neuronal death
Many studies now indicate that activated microglia are able to kill neurons 
(Klegeris and McGeer, 2000; Bal-Price and Brown, 2001; He et al., 2002; Park et al., 
2002) and the large microglial response observed in P14 me/me mice following cochlear 
ablation may affect neuronal survival in AVCN following deafferentation. To further 
elucidate the relationship between activated microglia and neuronal survival, P5, P I4, 
and P21 me/me and wild-type littermates received a unilateral cochlear ablation. Animals 
were allowed to recover for 4 days and the AVCN was then stained with either thionin or 
hematoxylin and eosin (H&E). Neurons displaying a normal morphology (including a 
well-defined cytoplasm and nuclear outlines, and a clearly visible nucleus with one or 
more nucleoli) were considered to be healthy cells and neuron counts were obtained for 
both the ablated and unablated AVCN.
Figure 4A-D demonstrate that in P5 mice, cochlear ablation results in a large 
amount of neuronal cell loss within AVCN in both me/me and wild-type mice. Neuron 
counts reveal that 54% of neurons within AVCN die following deafferentation in wild- 
type mice while 52% are lost in the deafferented me/me AVCN compared to the 
uninjured contralateral AVCN (Fig. 5 and Table 2). These results are consistent with
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Figure 4. H&E staining of neurons in P5 & P14 AVCN
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Figure 4: H&E staining of AVCN neurons in P5 and PI 4 wild-type and me/me mice 
after unilateral cochlear ablation and 4 day survival. Arrows point to some of the 
surviving neurons. At P5, approximately half numbers of neurons die within the ablated 
AVCN in both wild-type (B) and me/me (D) mice compared to their respective control 
sides (A and C), (arrows). Cochlear ablation at P14 results in a small amount of neuronal 
loss in the ablated wild-type AVCN (F) compared to the control side (E). In contrast, 
deafferentation in P14 me/me mice results in a significant amount of neuronal death 
within the ablated AVCN (H) compared to the control side (G), (arrows). This neuronal 
loss is less than that observed in both phenotypes at P5, but significantly higher than that 
seen in the P14 wild-type. Scale bar = 20 pm.
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Figure 5: Percent neuron loss in AVCN in wild-type vs. motheaten mice at P5, P14 and 
P21,4 days following unilateral cochlear ablation. At P5, approximately 50% of the 
neurons are lost in both wild-type and me/me mice following deafferentation (53.8 ±
11.5%, vs. 51.5 ± 7.2%, n = 4). At P14, me/me mice continue to demonstrate significant 
neuron loss (27.9 ± 3.7%, n = 4) compared to wild-type mice (12.7 ± 2.1%, n = 4). At 
P21, cochlear ablation does not induce significant neuron loss in animals of either 
phenotype. Wt, wild-type; me, me/me. Error bars indicate standard error of the mean. 
Asterisk, Mann-Whitney C/-test, p < 0.05.
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Table 2. Neuron number in AVCN 4 days post-ablation
Age at 
surgery
Total neuron number per side Percentage
Phenotype n -------------(mean ± SEM)------------- neuron loss1
Control Ablated (mean ± SEM)
P5
Wild-type
Me/me
4
4
7241 ± 749 
6489± 501
3453 ±1157 
3204± 564
53.8 ±11.5 
51.5 ±7.2
P14
Wild-type 4 7415 ±815 6507 ± 806 12.7 ±2.1
Me/me 4 6198 ± 171 4485 ± 174 27.9 ± 3.7 *
P21
Wild-type 4
Me/me
5702± 89 
5781 ±379
4976± 133 
5058 ± 341
12.6 ±3.4 
12.3 ± 2.9
P2 1  Wild-type 3 6328 ± 265
<—  J f a t a .  3 6 7 6 8 ± 3 5 0
Table 2. Neuron number within AVCN 4 days following unilateral cochlear ablation in 
wild-type vs. motheaten mice. Comparisons are made between age-matched wild-type 
and me/me mice. *Mann-Whitney {/-test, p < 0.05.
^h e  percentage of neuron loss is obtained as follows: 100 x (Total neuron number within 
control AVCN -  Total neuron number within ablated AVCN)/Total neuron number 
within control AVCN.
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those previously reported in B6/129 mice where cochlear ablation at P5 results in 50-60% 
neuronal cell loss within AVCN (Mostafapour et al., 2000).
In contrast, P14 wild-type mice exhibit a very small amount of deafferentation- 
induced neuronal cell death within AVCN (Fig. 4E and F). Neuron counts reveal that 
only 13% of neurons are lost within the deafferented AVCN of P14 wild-type mice (Fig. 
5, Table 2). However, a significant amount of neuronal cell death continues to occur in 
P14 me/me mice within the ablated AVCN (Fig. 4G and H). In these mice, about twice 
as much neuronal cell death (28%, p < 0.05) occurs in AVCN following deafferentation 
compared to wild-type mice (Fig. 5, Table 2) and this increased neuronal death is 
correlated with the increased microglial response observed in the P14 deafferented me/me 
AVCN. By P21, cochlear ablation results in very little neuronal loss within AVCN in 
both me/me and wild-type mice. Approximately 12% of P21 me/me AVCN neurons die 
following deafferentation while 13% of wild-type neurons are lost (Fig. 5 and Table 2). 
Taken together, these results demonstrate that loss of SHP-1 extends the window of 
neuronal susceptibility to cochlear ablation within AVCN beyond P14 but not beyond 
P21, and this neuronal death is correlated with the robust activation of microglial cells in 
these mice.
In order to confirm that neither loss of SHP-1 nor anesthesia affects the normal 
number of neurons within AVCN, a group of P21 wild-type and me/me mice received 
anesthesia alone, and neuron counts within AVCN were obtained. Table 2 demonstrates 
that there is no significant difference in the neuron number between non-surgical controls 
and the unablated sides of AVCN of all the three ages of injured animals, suggesting 
neither anesthesia nor lack of SHP-1 affects neuronal survival within AVCN.
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3.3. Astrocyte activation does not appear to be correlated with neuronal death
In contrast to the microglial response to deafferentation, the astrocyte response to 
cochlear ablation does not appear to be correlated in any way with neuronal survival and 
is similar in both the deafferented wild-type and me/me AVCN. Figure 6 and Table 3 
illustrates a similar trend towards increased GFAP immunoreactivity in AVCN at P5 and 
P21 in both wild-type and me/me mice 4 days following deafferentation, although this 
increase is not significant. Neither wild-type nor me/me mice at P 14 display changes in 
GFAP immunolabeling within AVCN after unilateral cochlear ablation. It should be 
noted that immunoreactivity for GFAP appears to increase in the unablated AVCN at P14 
(Fig. 6, 7A &C, and Table 3). The reasons for this are unclear.
To determine whether the timing of astrocyte activation is similar between the 
two phenotypes, P5 and P14 wild-type and me/me mice received a unilateral cochlear 
ablation and were allowed to survive for 2 ,4  or 6 days. The brains were then processed 
for GFAP immunohistochemistiy. At both P5 and PI4, astrocyte activation is similar in 
both the time course and the magnitude in wild-type and me/me mice within the ablated 
AVCN at all time points following cochlear ablation as showed in Figure 8A and B.
In summary, GFAP immunoreactivity tends to increase in the ablated AVCN 
following deafferentation but this increase is not significant. Thus, astrocyte activation 
does not appear to be correlated with the increased neuronal cell death observed atP14 in 
me/me mice.
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Figure 6. GFAP immunoreactivity in AVCN following deafferentation
25
Q.
iJ 20
z  o
G  »-
^  *  15
*r >O
0)
O a  
® cCL 3
E
E
2 10
o
■  wt-ctr 
E3wt-abl 
□  me-ctr 
0  me-abl
P5 P14 P21
Age at Cochlear Ablation
42
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
Figure 6: Percent of GFAP immunoreactivity within the control and ablated sides of 
AVCN in wild-type and me/me mice following deafferentation. At P5, there is a similar 
but non-significant increase in GFAP immunostaining in the ablated side compared to the 
control side in both wild-type (11.7 ± 3.3% vs. 5.9± 1.1%; n = 4) and me/me mice (16.4 ± 
2.7% vs. 10.0 ± 1.97%; n = 4). At P14, changes in GFAP immunoreactivity continue to 
be similar between the two phenotypes. There is a small increase in GFAP 
immunostaining in the ablated AVCN compared to the control AVCN in wild-type mice 
(19.3 ± 1.8% vs. 17.5 ± 1.8%; n = 4); and a larger but not significant elevation of GFAP 
immunoreactivity in the ablated AVCN compared to the control AVCN in me/me mice 
(22.7± 0.8% vs. 15 ± 2.4%; n = 4). At P21, both phenotypes exhibit a similar increase in 
GFAP immunoreactivity after cochlear ablation. Note that the basal level of GFAP 
immunoreactivity in me/me mice on the control side (11.9 + 2%) is significantly higher 
than that in wild-type mice (4.4 ± 1.3%). Wt-ctr, wild-type control side; wt-abl, wild-type 
ablated side; me-ctr, me/me control side; me-abl, me/me ablated side. Error bars indicate 
standard error of the mean. Asterisk, Mann-Whitney U-test, p < 0.05.
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Figure 7. GFAP+ astrocytes in P14 wild-type vs. melme AVCN
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Figure 7: GFAP immunostaining in AVCN of wild-type vs. motheaten mice at P14,4 
days following cochlear ablation. Wild-type AVCN shows slightly increased GFAP 
labeling on the ablated side (B) compared to the control side (A) after the cochlear 
ablation (arrows). There is a larger, but non-significant increase in GFAP+ astrocytes on 
the ablated side (D) compared to the control side (C) of me/me AVCN (arrows). Scale bar 
= 2 0  pm.
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Table 3. Quantification of GFAP immunoreactivity
Age at 
surgery Phenotype n
Percent of GFAP staining (mean ± SEM)
Control Ablated
P5
Wild-type
Me/me
4
4
5.87 ± 1.14 
10.03 ± 1.97
11.70 ±3.28 
16.43 ±2.70
P14
Wild-type 4 
Me/me
17.50 ±1.78 
14.99 ± 2.36
19.30 ± 1.83 
22.66 ± 0.83
P21
Wild-type
Me/me
4 4.43 ± 1.34
5 11.94 ±2.01 *
10.50 ± 2.44 
19.19 ±2.39
Table 3. Percent of AVCN immunopositive for GFAP staining in wild-type vs. 
motheaten mice 4 days following cochlear ablation. The percent AVCN immunopositive 
for GFAP staining was obtained by dividing the sum of the stained area (pm ) that 
reached threshold within AVCN by the sum of the area of AVCN (pm2) from three 
representative sections. Comparisons are made between age-matched wild-type and 
me/me mice. *Mann-Whitney {/-test, p < 0.05.
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Figure 8: Time course of GFAP immunoreactivity at 2,4, and 6 days following cochlear 
ablation in the deafferented AVCN of P5 and P14 wild-type and me/me mice. Both the 
time course and magnitude of the GFAP immunolabeling are similar in both P5 (A) and 
P14 (B) wild-type and me/me mice at all three time points following cochlear ablation. 
Error bars indicate standard error of the mean. Asterisk, Mann-Whitney £/-test, p < 0.05.
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4. Discussion
The current study demonstrates that lack of the tyrosine phosphatase SHP-1 
results in a significant increase in microglial activation following unilateral cochlear 
ablation in P14 mice, that is correlated with an extension of the critical period for 
deafferentation-induced neuronal cell death within AVCN beyond PI4. While previous 
studies have suggested that the transition of AVCN neurons from afferent-dependent to 
afferent-independent mechanisms relies on the establishment of mature synaptic 
connections from the eighth nerve (Rubel and Fritzsch, 2002), we hypothesize that the 
large microglial response in me/me mice may significantly contribute to neuronal cell loss 
following deafferentation. It is interesting to note that astrocyte activation does not 
appear to be correlated with the survival of AVCN neurons.
4.1. Synaptic maturation in AVCN
The onset of hearing in the mouse occurs at PI 1-14 (Limb and Ryugo, 2000) 
suggesting that the critical period for deafferentation-induced cell death is defined by the 
activation of eighth nerve synapses onto AVCN neurons (Rubel and Fritzsch, 2002). Our 
data indicates that microglial activation as well as synaptic maturation are coexisting 
factors that determine the extension of the critical period for neuronal susceptibility in 
me/me mice. In addition, our results indicate that at P5, activated microglia are able to 
induce neuronal loss in both phenotypes at a time when synaptic connections onto AVCN 
neurons are very immature. At P21, activated microglia are no longer able to induce
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neuronal death in either phenotype because functional synaptic connections are mature 
and confer some protection onto AVCN neurons. However, at P14, synaptic connections 
are just maturing, and AVCN neurons are still vulnerable to microglia-induced neuronal 
death if the microglial response is large enough, as is the case in the me/me mice.
An important point is that the motheaten auditory system appears to mature at the 
same rate as the wild-type auditory system. Examination of wholemounted me/me 
cochlea reveals no obvious differences in hair cell number or distribution compared to 
wild-type (Dabdoub and Kelley, personal communication). In addition, both wild-type 
and me/me mice show a startle response at P14, and both phenotypes display a similar 
pattern of synaptophysin immunoreactivity within AVCN at P14 (Zhao, Brooks and 
Lurie, personal observations). Synaptophysin immunoreacts with presynaptic vesicles of 
CNS neurons, indicating that presynaptic connections within AVCN are morphologically 
similar between wild-type and me/me mice at PI 4. Thus, the extension of the critical 
period in me/me mice is not due to delayed maturation of the auditory system, lending 
further support to our hypothesis that activated microglia play a role in defining the 
critical period of neuronal loss within AVCN following deafferentation.
4.2. Role o f SHP-1 in microglial activation
The extensive activation of microglia observed in the me/me mutants following 
deafferentation suggests that lack of the protein tyrosine phosphatase SHP-1 may play a 
role in regulating the glial response to injury. Previous studies in our laboratory have 
demonstrated that SHP-1 increases in a subset of glial cells following deafferentation of
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the avian auditory brainstem and both in vivo and in vitro studies show that these SHP-1+ 
glia do not appear to enter the cell cycle (Lurie et al., 2000; Sorbel et al., 2002). We have 
also found that ischemic damage to the mouse forebrain results in the upregulation of 
SHP-1 in non-proliferating mammalian glial cells, with the expression of SHP-1 in 
microglia occurs at early times (day 1) after the ischemic injury (Wishcamper et al., 
2003). Notably, ischemic lesion of the SHP-1 deficient me/me mouse brain results in a 
significantly larger microglial response compared to the same damage induced in wild- 
type mice (Wishcamper and Lurie, personal observation), suggesting that SHP-1 
negatively regulates microglial activation in the mammalian brain following injury.
It should be noted that SHP-1 is predominantly expressed in hematopoietic cells 
and lack of SHP-1 results in a variety of hematopoietic abnormalities in me/me mice, 
including overproduction of macrophages and/or immune dysfunction (Shultz and Green, 
1976; Shultz et al., 1997). The robust response of me/me microglia to deafferentation and 
other CNS injuries is possibly due to both local activation of resident microglia and 
peripheral infiltration of circulating macrophages as an inflammatory reaction (Priller et 
al., 2001; Hanisch, 2002; Raivich et al., 2003). Studies in our laboratory have also found 
that, due to lack of SHP-1, the uninjured P14 me/me brainstem expresses a reduced level 
of the anti-inflammatory cytokine IL-10 and an elevated level of the pro-inflammatory 
cytokine IL-ip. In addition, following cochlear ablation in me/me mice there is a 
decreased induction of the anti-inflammatory cytokines IL-4 and IL-10 and an increased 
induction of IL-ip at 1 day compared to the wild-type brain, suggesting a role for SHP-1 
in mediating the activation of microglia (Zhao and Lurie, personal observation).
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4.3. Microglial activation-induced AVCN neuronal death
Accumulating evidence indicates that activated microglia can kill neurons both in 
vivo and in vitro through a variety of mechanisms. It has been suggested that the release 
of nitric oxide (NO) (Loihl and Murphy, 1998; Liberatore et al., 1999; Bal-Price and 
Brown, 2001), reactive oxygen species (Beckman et al., 1994; Chao et al., 1995), TNF-a 
and IL-ip (Chao et al., 1995; Viviani et al., 1998; He et al., 2002), and glutamate (Barger 
and Basile, 2001) by activated microglia all contribute to neuronal death following injury 
and disease. In particular, the release of inducible nitric oxide synthase (iNOS) derived 
NO is thought to inhibit neuronal respiration, causing glutamate release and the 
subsequent excitotoxic death of neurons (Bal-Price and Brown, 2001). In addition, 
activated microglia themselves secrete glutamate (Barger and Basile, 2001) and may also 
induce glutamate release from astrocytes via NO induction (Bal-Price and Brown, 2001). 
Increased induction of iNOS and TNF-a through activation of the extracellular signal 
regulated kinase (ERK) and p38 MAP kinase subgroups of MAP kinases (MAPK) occurs 
in both microglia and astrocytes (Bhat et al., 1998).
One possible link between SHP-1 and microglial activation may be the ERK and 
p38 MAPK pathways. Endotoxin LPS and adenovirus infection-activated microglia show 
increased induction of iNOS and TNF-a through activation of both the ERK and p38 
subgroups ofMAPKs (Bhat et al., 1998; Bhat and Fan, 2002) and hypoxia induces iNOS 
expression and NO release from activated microglia via p38 MAPK (Park et al., 2002). 
Significantly, SHP-1 has been shown to inhibit ERK activity (Shibasaki et al., 2001) and 
to indirectly inhibit p38 MAP kinase (Kumar et al., 1999). This raises the possibility that
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SHP-1 is associated with negative regulation of ERK and/or p38 MAPK within 
microglia, with loss of SHP-1 leading to increased activation of ERK and/or p38 MAP 
kinase in me/me microglia and subsequent induction and release of NO and TNF-a. This 
in turn might result in death of AVCN neurons following deafferentation, particularly at 
P14 when these neurons are still vulnerable.
Finally, it will be of interest to determine whether excessive microglial activation 
can induce death of AVCN neurons that have been protected from deafferentation- 
induced cell loss. Mostafapour et al. (2002) have recently shown that bcl-2 
overexpression eliminates neuronal death within AVCN in very young mice, suggesting 
that upregulation of bcl- 2  can rescue neurons from deafferentation-induced death even 
during the critical period when they are normally susceptible. It is not known whether 
microglial activation can induce neuronal death in AVCN neurons that overexpress bcl-2. 
Future experiments will address this issue.
5. Conclusion
In summary, cochlear ablation in mice lacking functional SHP-1 protein extends 
the critical period for deafferentation-induced neuronal death beyond P14. This neuronal 
loss is correlated with extensive microglial activation within the me/me AVCN. Our data 
suggests that the critical period for neuronal survival within the murine auditory 
brainstem may depend upon the timing and extent of microglial activation as well as 
other intrinsic factors such as synaptic maturation and/or apoptotic mediators.
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CHAPTER TWO
Loss of SHP-1 phosphatase selectively alters cytokine expression following 
cochlear ablation
Abstract
Inflammatory cytokines in the central nervous system are largely modulated by 
glial cells and play a crucial role in regulating neuronal responses to CNS injury. The 
protein tyrosine phosphatase SHP-1, an intracellular regulator of many cytokine signaling 
pathways, has also been implicated in mediating the activation of glia. Previous studies 
have demonstrated a direct correlation between abnormally activated microglia and 
neuron loss within the SHP-1 deficient motheaten (me/me) mouse auditory brainstem 
after afferent injury. In order to determine whether loss of SHP-1 creates an aberrant 
cytokine environment that could drive the abnormal activation of me/me microglia, the 
expression of five different inflammatory cytokines, interleukin-4 (IL-4), interleukin-10 
(IL-10), interleukin-1 beta (IL-lp), tumor necrosis factor-alpha (TNF-a), and interferon- 
gamma (IFN-y) was examined by enzyme-linked immunoabsorbent assay (ELISA) in the 
intact and deafferentated me/me and wild-type hindbrain. Normal uninjured me/me mice 
showed decreased IL-10 but increased IL-ip levels. One day following unilateral 
cochlear ablation, expression of IL-4 and IL-10 in me/me brains is significantly less than 
in wild-type, whereas the level of IL-1P in these mutants is significantly increased 
compared to wild-type. The production of TNF-a and IFN-y is reduced in the me/me 
brain at day 4 after deafferentation. Taken together, these results indicate that lower 
levels of the anti-inflammatory cytokines IL-4 and IL-10, in combination with elevated 
expression of the pro-inflammatory cytokine IL-ip shortly after injury, may initiate a 
severe inflammatory reaction within the me/me brain, leading to activation of microglia 
and contributing to the neuronal degeneration in the deafferented auditory brainstem.
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1. Introduction
Afferent deprivation of the auditory system leads to neuronal loss and 
degeneration within the cochlear nucleus of the auditory brainstem in both avian and 
mammals during early stages of postnatal development (Trune, 1982; Webster, 1983; 
Bom and Rubel, 1985; Hashisaki and Rubel, 1989; Tiemey et al., 1997; Edmonds et al., 
1999; Mostafapour et al., 2000). However, the underlying physiological mechanisms that 
determine whether neurons survive or die following deafferentation are not fully 
understood. Glial cells, especially microglia, have recently received much attention as 
mediators of neuronal survival and/or death following injury, infection or other 
neuropathological states (Streit, 1996; Aschner et al., 1999; Bruce-Keller, 1999; Streit et 
al., 1999). Previous studies in our laboratory have demonstrated that after unilateral 
cochlear ablation, there is a direct correlation between microglial activation and neuronal 
cell loss within the auditory brainstem nucleus, anteroventral cochlear nucleus (AVCN) 
of the SHP-1 deficient motheaten (me/me) mice at postnatal day 14 (P14), a time when 
these neurons are normally resistant to deafferentation-induced death (Zhao and Lurie, 
submitted).
During neural injury and repair, a unique immunoregulatory function of microglia 
is to help drive the cytokine network by producing and responding to a variety of 
cytokines and chemokines (Sawada et al., 1999; Hanisch, 2002). The activation of 
microglia following injury is thought to be partially regulated by the cytokine 
environment through the expression and activation of pro- and/or anti-inflammatory 
cytokine receptors on these cells (Sawada et al., 1999; Basu et al., 2002; John et al.,
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2003), leading to the initiation of intracellular cytokine signaling and a subsequent 
inflammatory response. Many of the inflammatory cytokines produced by activated 
microglia are deleterious to neurons. A variety of in vitro studies (Ma et al., 2002; Eskes 
et al., 2003; Li et al., 2003) provide support for the concept that overactivation of 
microglia within damaged neural tissue in vivo could produce excessive amounts of 
harmful cytokines such as the pro-inflammatory cytokines IL-ip and TNF-a, triggering 
the degeneration of neighboring neurons.
Microglial proliferation and activation is thought to involve, at least in part, 
phosphorylation events that are governed by the antagonistic activities of protein tyrosine 
kinases (PTKs) and protein tyrosine phosphatases (PTPs) (Horvat et al., 2001). SHP-1 is 
a cytoplasmic protein tyrosine phosphatase containing two src-homology 2  domains 
(SH2). It has been implicated in the regulation of various cytokine signaling pathways 
(You and Zhao, 1997; Hilton, 1999; Xie et al., 2000; Kile et al., 2001), as well as in 
modulating astroglial and microglial proliferation and differentiation (Massa and Wu, 
1998; Lurie et al., 2000; Wishcamper et al., 2003). Loss of functional SHP-1 in 
motheaten mice results in both immunodeficiency and autoimmune defects including lack 
of a T and B cell response to antigen (Shultz and Green, 1976; Davidson et al., 1979; 
Stanton et al., 1985). However, little is known about how SHP-1 regulates the immune 
functions elicited by activated glia in the central nervous system following brain injury.
The current study aims to elucidate the role of SHP-1 in modulating the 
production of anti- and pro-inflammatory cytokines during brain injury. Previous studies 
have shown deafferentation results in abnormally activated microglia with a 
corresponding increase in neuronal loss in me/me mutants at age P14 but not at P5 or
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P21. Here we examined the P14 wild-type and me/me brainstem for expression of the 
cytokines IL-4, IL-10, IL-ip, TNF-a, and IFN-y before and after a unilateral cochlear 
ablation in order to determine whether the cytokine environment in me/me mice favors 
abnormal microglial activation following deafferentation. Normal, uninjured me/me mice 
show a reduced expression of the anti-inflammatory cytokine IL-10 and an enhanced 
expression of the pro-inflammatory cytokine IL-ip. Following deafferentation, down- 
regulation of both IL-4 and IL-10 in conjunction with up-regulation of IL-ip is observed 
in me/me brains when compared to the wild-type mice at day 1 post-injury. In contrast, 
levels of TNF-a and IFN-y in these mutants decrease at later times (day 4 post-injury), 
well after the onset of microglial activation (Zhao and Lurie, submitted). These results 
suggest that a decrease in the anti-inflammatory cytokines combined with an elevation of 
the pro-inflammatory cytokine IL-lp early after the injury may drive the abnormal 
activation of me/me microglia following cochlear ablation. This in turn, may potentiate 
the death of AVCN neurons in the face of afferent deprivation.
2. Materials and methods
2.2. Animals
The founding mice (C3¥eLc.B6-a/a-Hcphme/+) were obtained from The Jackson 
Laboratory (Bar Harbor, ME). Homozygous me/me mutants and +/+ wild-type progeny 
used in this study were propagated by +/me matings. Mice were given food and water ad
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libitum, and were placed in a 1 2 -hour light/dark cycle, constant temperature and humid 
environment. All animal procedures were in strict accordance with the NIH Guide for 
the Care and Use o f Laboratory Animals and were approved by the University of 
Montana Institutional Animal Care and Use Committee.
2.2. Mouse Genotyping
Polymerase chain reaction (PCR) amplification of a 426-bp fragment, which 
encompasses the site of the me/me mutation, was utilized to genotype the mice. The PCR 
reaction was carried out using forward (5'-CGCTGCTGCTCATGTATCTC-3') and 
reverse (5 '-GCCT AC AGAGGG AAG AGGCT-3') primers (Operon Technologies, 
Alameda, CA) and the PCR Master Mix (Promega Corporation, Madison, WI). Briefly, 
2-3 mm tail samples were digested in 100 mM NaOH at 65°C for 3 hours. Digestion was 
terminated by adding 0.75 M Tris-HCl (pH 7.5) prior to centrifugation. DNA was 
subjected to 35 cycles consisting of: 30 seconds at 95°C, 1 minute at 56°C, and 1 minute 
at 72°C. The amplified PCR products were digested for 1 hour with TaqI enzyme (New 
England BioLabs, Beverly, MA) at 65°C and separated by 1.2% agarose gel 
electrophoresis at 120 V for 100 minutes. PCR products were stained with ethidium 
bromide and visualized by UV light.
2.2. Unilateral Cochlear Ablation
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Wiid-type mice and me/me mutants at P14 (n = 5) were anesthetized with 2,2,2- 
tribromoethanol (375 mg/kg, i.p.) and received a unilateral cochlear ablation. Surgeries 
were performed as previously described with some modifications (Mostafapour et al., 
2000). Briefly, the right ear pinna inferior region was shaved and an incision was made 
on the inferior side of the pinna. The ear canal was enlarged by making further incision 
at its entry, and the tympanic membrane was punctured and the ossicles were removed 
using a pair of fine forceps. The basal turn of the cochlea was visualized and destroyed 
with RS-5610 ultra fine scissors (Roboz Surgical Instrument Company, Rockville, MD) 
followed by aspiration of its contents using a 27-gauge needle with a blunt tip connected 
to a vacuum pump. The incision was closed with cyanoacrylic glue. All surgical 
procedures were performed on a warming pad and animals were given oxygen inhalation 
after surgery on a heating element until they were fully awake. Following the operation, 
mice were returned to their parents and allowed to survive for 1,2, or 4 days.
2.4. Brain Tissue preparation
Unoperated P14 wild-type and me/me mice were used for normal uninjured 
control groups. Mice receiving a unilateral cochlear ablation were allowed to survive for
1,2, or 4 days after the surgery. All mice used in this study were sacrificed by 
decapitation after deep anesthetization with 2,2,2-tribromoethanol (> 375 mg/kg, i.p.). 
The brains were rapidly removed and cut to separate brainstem-cerebellum from 
forebrain and control side from ablated side. The brain pieces were then immediately 
frozen in liquid nitrogen and stored at -80°C until use. A modified RIPA buffer
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composed of 150 mM NaCl, 50 mM Tris-HCl, 1% sodium deoxycholate, 1% Triton X- 
100, 1 mM EDTA, 2 pg/ml aprotinin, 2 pg/ml leupeptin, with addition of 1 mM PMSF 
immediately before application, was used to homogenize of the brain tissue pool of each 
group (n = 3-5) at 1 ml buffer/brainstem-cerebellum. Brain homogenates were 
centrifuged at 3220 x g for 10 minutes at 4°C, and supernatants containing extracted 
proteins were aliquoted and frozen at -80°C until needed for subsequent enzyme-linked 
immunosorbent assays (ELISA).
2.5. Measurement o f cytokines by ELISA
The total protein concentrations in the brain tissue lysates were analyzed at 1:50 
dilution by commercially available BCA Protein Assay Reagent (Pierce, Rockford, IL) to 
normalize cytokine contents within the lysates. Cytokine levels for IL-4, IL-10, IL-lp, 
TNF-a, and IFN-y were measured using the respective mouse cytokine ELISA kit 
according to the manufacturer’s instructions (BD Pharmingen, San Diego, CA).
Undiluted samples were used for all cytokine measurement with the exception of IL-lp 
which was measured at 1:50 dilution. Brain tissue protein extracts were added to Nunc- 
Immuno™ Maxisorp™ 96-well plates (VWR International) coated with anti-mouse IL-4, 
IL-10, IL-lp, TNF-a, or IFN-y monoclonal antibodies. Specific cytokine contents were 
detected by treating the plates with respective biotinylated mouse monoclonal antibodies 
with avidin-horseradish peroxidase conjugate. Enzyme substrate solution (BD 
Pharmingen) containing tetramethylbenzidine (TMB) was added to generate a color 
product and the reactions were terminated by adding stop solution (1 M H 3 P O 4 )
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immediately before the absorbance was read at 450 nm. A recombinant mouse antibody 
specific to each cytokine contained within the kit was utilized to generate a standard 
curve and included in each assay.
2.6. Statistical analyses
Data were produced from three independent preparations containing a pool of 
brains (n = 3-5). ANOVA unpaired /-test was used for statistical analyses on the cytokine 
expression of the uninjured wild-type and me/me brain tissue. The cytokine responses 
within the injured mouse brains were expressed as percentage of control (uninjured wild- 
type brains). The non-parametric Mann-Whitney U-test was employed. The data are 
presented as the mean ± standard error of the mean (SEM), p < 0.05 was considered 
significant.
3. Results
3.1. Loss of SHP-1 is associated with down-regulation ofIL-10 and up-regulation oflL- 
1 fi in the mouse hindbrain
Previous studies have demonstrated that loss of SHP-1 is associated with 
abnormal activation of microglia and neuronal loss within AVCN of the mouse auditory 
brainstem following cochlear ablation at P14 (Zhao and Lurie, submitted). Because 
immune dysfunction is a trait of SHP-1 deficient me/me mice, this study is designed to
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investigate whether inflammatory cytokines participate in the mediation of microglial 
activation and CNS neuronal survival after afferent injury to the murine auditory 
brainstem.
To determine whether loss of SHP-1 alters the production of cytokines in the 
intact mouse brainstem, normal uninjured P14 wild-type and me/me brainstem- 
cerebellum tissues were processed for multiple cytokine ELISAs. The expression of anti­
inflammatory (LL-4 and IL-10) and pro-inflammatory (IL-ip, TNF-a and IFN-y) 
cytokines were evaluated and compared between the two genotypes (Fig. 9).
The anti-inflammatory cytokines IL-4 and IL-10 are expressed at a lower level in 
the uninjured me/me hindbrain compared to wild-type, although only levels of IL-10 are 
significantly decreased (Fig. 9Ai & A2 ; p < 0.05). The expression of IL-10 is reduced 
from 32.6 pg/mg protein in the wild-type mice to 27.3 pg/mg protein in the me/me mice 
(Fig. 9 A2). In contrast, there is a 33% increase in the levels of the pro-inflammatory 
cytokine IL-ip in the me/me brainstem compared to wild-type mice (Fig. 9Bi, p < 0.01). 
The additional two cytokines usually involved in the triggering of inflammatory 
reactions, TNF-a and IFN-y, are not significantly increased in the me/me mouse 
brainstem compared to wild-type (Fig. 9 B2 & B3).
3.2. Me/me mice show reduced levels o f anti-inflammatory cytokines 1 day after 
deajferentation
P14 wild-type and me/me mice were subjected to unilateral cochlear ablation and 
were allowed to survive for 1,2, or 4 days. Both the deafferented (ipsilateral) and
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Figure 9. Cytokine profile in the intact hindbrain
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Figure 9. Differential cytokine expression detected by ELISA in uninjured wild-type vs. 
me/me brain at P14. Motheaten mice show significantly reduced levels of the anti­
inflammatory cytokine IL-10 (A2 , p < 0.05) but not IL-4 (Ai) in the brainstem-cerebellum 
compared to wild-type, although IL-4 levels show a downward trend in these mutants. In 
contrast, of the three pro-inflammatory cytokines measured, only IL-ip (Bi, p < 0.01) 
expression is significantly increased in the me/me hindbrain. Data are generated from 
three independent preparations and presented as pg cytokine per mg total protein. Error 
bars indicate standard error of the mean. Asterisk, significant difference by ANOVA 
unpaired Mest.
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uninjured (contralateral) sides (data not shown) of the hindbrain were processed for 
cytokine expression. Significant decreases in IL-4 and IL-10 expression are found in the 
injured me/me hindbrain compared to wild-type 1 day after afferent deprivation but not at 
later times (Fig. 10; p < 0.05). Specifically, me/me mice demonstrate a reduced level of 
IL-4 expression that is approximately 85% of the wild-type uninjured controls at 1 day 
(Fig. 10A). However, by 2 and 4 days following deafferentation, me/me mice are 
producing similar levels of IL-4 as wild-type. In contrast, cochlear ablation in wild-type 
mice results in an increase of IL-4 expression that is approximately 115% of the 
uninjured wild-type 1 day after the injury (Fig. 10A).
IL-10 levels follow a similar pattern as that seen for IL-4. Following cochlear 
ablation, IL-10 production in the me/me hindbrain is approximately 85% of the uninjured 
wild-type and is significantly less than that observed in the deafferented wild-type 
brainstem (Fig. 10B; p < 0.05). IL-10 expression in me/me mice then increases at 2-4 
days post-injury to similar levels as that observed in wild-type mice (Fig. 10B). IL-10 
expression in the wild-type hindbrain remains relatively stable over the 1-4 days post­
injury at about 100-110% of the uninjured controls (Fig. 10B). It should be noted that IL- 
4 and IL-10 expression levels in the me/me hindbrain at 1 day following deafferentation 
are similar to the levels seen in the uninjured me/me brain. Our results demonstrate that 
following cochlear ablation in me/me mice, not only are the levels of the anti­
inflammatory cytokines IL-4 and IL-10 less than wild-type at 1 day, but their induction is 
delayed.
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Figure 10. Decreased IL-4 & IL-10 in the injured me/me hindbrain
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Figure 10. Me/me mice display decreased anti-inflammatory cytokine expression 1 day 
after unilateral cochlear ablation. A. IL-4 expression in the injured ipsilateral side of 
wild-type and me/me hindbrain post-surgery. Levels of the anti-inflammatory cytokine 
IL-4 in me/me mice are significantly lower than wild-type at 1 day post-ablation (p < 
0.05) but are similar to wild-type at days 2 and 4. B. IL-10 expression in the injured 
ipsilateral side of wild-type vs. me/me hindbrain post-surgery. Expression of the anti­
inflammatory cytokine IL-10 in me/me mice is significantly decreased compared to wild- 
type mice at 1 day (p < 0.05) but not at 2 or 4 days following the cochlear ablation. Data 
are presented as percentage of wild-type uninjured control. Error bars indicate standard 
error of the mean. Asterisk, significance determined by non-parametric Mann-Whitney 
U- test.
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3.3. Me/me mice show enhanced levels o f the pro-inflammatory cytokine IL-lfl 1 day 
following deafferentation
At 1 day after cochlear ablation, significantly elevated levels of IL-ip (~120% of 
control) are observed in the me/me hindbrain compared to the wild-type animals (90% of 
control) (Fig. 11; p < 0.05). There is no difference in IL-ip expression between the two 
genotypes of mice at 2 days. However, both genotypes display an up-regulation of IL-ip 
levels at 4 days as shown in Figure 11. Although IL-ip expression appears to be 
increased in me/me mice compared to wild-type mice at this later time, it is not 
statistically significant due to the large variability in the me/me groups.
3.4. TNF-a and IFN-y decrease in the me/me hindbrain 4 days after cochlear ablation
Unlike the cytokine levels presented above, expression of the pro-inflammatory 
cytokines TNF-a and IFN-y are similar between the two genotypes at 1 and 2 days post­
injury at 100-120% of the wild-type controls (Fig. 12). However, by 4 days after the 
injury, both TNF-a and IFN-y levels in the me/me hindbrain are significantly decreased 
compared to wild-type (Fig. 12; p < 0.05).
4. Discussion
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Figure 11. Increased IL-ip in the injured me/me hindbrain
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Figure 11. Increased expression of the pro-inflammatory cytokine IL-ip in the me/me 
hindbrain following unilateral cochlear ablation. IL-ip levels in response to cochlear 
ablation are significantly elevated in the deafferented me/me hindbrain 1 day after the 
injury. By 4 days post-treatment, IL-lp levels appear to be enhanced in both wild-type 
and me/me mice, but there is no significant difference between the two genotypes due to 
the large variability in the me/me mice. Data are presented as percentage of wild-type 
uninjured control. Error bars indicate standard error of the mean. Asterisk, significance 
determined by non-parametric Mann-Whitney 17-test.
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Figure 12. Me/me mice demonstrate decreased levels of TNF-a and IFN-y expression in 
the injured hindbrain 4 days following cochlear ablation. A. TNF-a expression in the 
injured ipsilateral side of wild-type and me/me hindbrain is similar between the 2 
genotypes at 1 and 2 days post-injury. At 4 days post-ablation, TNF-a expression is 
significantly decreased in the me/me brain compared to wild-type. B. Similar to the 
pattern of TNF-a expression, IFN-y levels are similar between the two genotypes at 1 and 
2 days post-ablation. However, there is a significant decrease in IFN-y levels in me/me 
brain at 4 days post-injury compared to wild-type. Data are presented as percentage of 
wild-type uninjured control. Error bars indicate standard error of the mean. Asterisk, 
significance determined by non-parametric Mann-Whitney f/-test.
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Our results demonstrate that lack of SHP-1 leads to significantly decreased levels
of the anti-inflammatory cytokine IL-10 and increased levels of the pro-inflammatory
cytokine IL-lp in the intact me/me hindbrain. Unilateral cochlear ablation results in
decreased levels of the anti-inflammatory cytokines IL-4 and IL-10 in conjunction with
increased levels of the pro-inflammatory cytokine IL-ip in me/me mutants compared to
wild-type at 1 day post-injury. However, the cytokine levels in the injured me/me mice at
this time point are similar to uninjured me/me mice, indicating that cytokine induction is
delayed in mice lacking SHP-1. Nonetheless, the fact that me/me mice have decreased
levels of anti-inflammatory cytokines and increased levels of the pro-inflammatory
cytokine IL-ip at 1 day after cochlear ablation, creates a cytokine environment that is
favorable for excessive microglial activation, and this is what is observed in deafferented
me/me mice (Zhao and Lurie, submitted). The expression of the pro-inflammatory
«
cytokines TNF-a and IFN-y is reduced 4 days following deafferentation in me/me mice 
compared to wild-type, well after microglial activation has occurred (Zhao and Lurie, 
submitted).
4.1. Regulation o f cytokine expression by SHP-1 in the intact brains
SHP-1 has been demonstrated to modulate cytokine production in the immune 
system. Stanton et al. (1985) has reported that splenocytes from SHP-1 deficient 
motheaten mice lack the ability to utilize exogenous cytokines IL-1 or IL-2, and produce 
less IL-2 upon alloantigen stimulation. In addition, motheaten viable (Mev) mice which 
contain SHP-1 that is only 20% active, express elevated levels of IL-6, IL-10, TNF, and
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IFN-y in sera as well as in cultured B and T cells, and decreased levels of IL-2 in sera and 
activated T cells (Khaled et al., 1998).
The present study extends our understanding of the regulation by SHP-1 of 
cytokine production in the CNS. In contrast to the finding of increased IL-10 expression 
in the Mev mouse sera and B and T cells (Khaled et al., 1998), me/me mice show reduced 
levels of this anti-inflammatory cytokine in the uninjured me/me mouse hindbrain 
compared to the age-matched wild-type animals at P14. Among all cell types in the 
brain, microglia, and possibly astrocytes, are the major sources of IL-10 (Benveniste, 
1997; Aloisi, 2001; Dong and Benveniste, 2001; Ledeboer et al., 2002). The numbers of 
immunolabeled glia in the intact me/me brain have been shown to be significantly less 
than that in wild-type mice (Wishcamper et al., 2001), which may explain the decreases 
in IL-10 expression in these animals. Besides synthesis of cytokines by resident 
microglia, circulating blood as well as invading peripheral macrophages and monocytes 
into the brain could also contribute to the total quantity of cytokines measured in brain 
tissue. Because IL-10 has been shown to inhibit macrophage costimulatory activity and 
macrophage activation and intracellular signaling of a number of different systems 
(Oswald et al., 1992; Ding et al., 1993), it is not surprising to see reduced expression and 
function of IL-10 in the me/me hindbrain as motheaten mice possess hematopoietic 
abnormalities including overproduction of neutrophils and macrophages (Shultz and 
Green, 1976; Shultz et al., 1997).
Our data also show an increased expression of IL-lp in uninjured me/me mice, 
which is interesting because to date, there has been no indication that SHP-1 is involved 
in the regulation of IL-lp. Since both astrocytes and microglia can produce IL-ip, it
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would be expected that decreased levels of IL-1J3 would be found in me/me mice who 
have reduced numbers of glial cells. However, the anti-inflammatory cytokine IL-10, 
previously designated as cytokine synthesis inhibitory factor (CSIF) (O'Garra et al., 1990; 
de Waal Malefyt et al., 1991), has the capacity to inhibit the production and signaling of a 
wide range of pro-inflammatory cytokines and chemokines including IL-la, IL-lp, IL-6, 
TNF-a, IFN-y and MCP-1 (Frei et al., 1994; Balashov et al., 2000; Szczepanik et al., 
2001; Ledeboer et al., 2002). With reduced levels of IL-10, the inhibition of IL-lp 
production is therefore diminished. Furthermore, since monocytes and macrophages can 
both produce IL-ip (Kiefer et al., 2001; Peracoli et al., 2003), the up-regulation of IL-ip 
expression seen in the me/me brains could be partly due to its secretion from the larger 
numbers of monocytes/macrophages that occur as a result of SHP-1 deficiency.
It is intriguing to note that loss of SHP-1 does not affect expression of the two 
other pro-inflammatory cytokines, TNF-a and IFN-y. This could be the outcome of 
balancing between enhanced production of TNF-a and IFN-y due to decreased inhibition 
by IL-10, and the reduced numbers of natural killer cells, the primary producer of IFN-y, 
in motheaten mice (Clark et al., 1981). These results demonstrate the complexity of the 
cytokine network in the CNS and highlight the fact that SHP-1 appears to modulate 
cytokine levels both directly and indirectly. Nevertheless, the combination of low levels 
of IL-10 and high levels of IL-lp within the me/me hindbrain appears to set up an 
environment that is conducive to microglial activation upon injury.
4.2. Cytokine induction o f microglial activation
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One of the prominent properties of microglia is the ability to respond promptly to 
signals like cytokines/chemokines and to gain antigen-presenting capacity by expressing 
major histocompatibility complex (MHC) I or II molecules, allowing initiation of 
antigen-specific immune responses of the damaged CNS (Neumann, 2001). Under 
infectious and inflammatory conditions, a variety of inducible cytokine receptors can be 
constitutively expressed on the surface of microglia, ranging from receptors for the pro- 
inflammatory cytokines IL-1, TNF, IFN-y, IL-12 to receptors for the anti-inflammatory 
cytokines IL-4, IL-10, TGF-P (Aloisi, 2001). Binding of these cytokines to their 
respective receptors then triggers or amplifies innate immune responses of microglia 
(pro-inflammatory) or diminishes immune mediated reactions elicited by microglia (anti­
inflammatory).
The altered cytokine environment in injured me/me mice appears to push the 
microglia into a pro-inflammatory pathway. These abnormally activated microglia may 
in turn, produce significant amount of pro-inflammatory cytokines such as IL-lp, IL-6, 
and/or neurotoxic substances like nitric oxide that are dangerous to the already impaired 
CNS, potentiating the degeneration of adjacent auditory nucleus neurons.
Interestingly, the expression of the pro-inflammatory cytokines TNF-a and IFN-y, 
two common stimulators of monocytes/macrophages/microglia, is reduced at 4 days post­
injury in the me/me brain. It should be noted that these cytokines have a similar 
expression in both me/me and wild-type mice before and at early times after the injury. 
Increased expression of IL-4 and IL-10 at later times post-injury may exert an inhibition 
on the induction of these two pro-inflammatory cytokines in me/me mice, leading to their
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decreased expression at 4 days post-injury. Thus, TNF-a and IFN-y appear to not be 
involved in the deafferentation-induced microglial response in mice lacking SHP-1.
5. Conclusion
The current study provides insight into the modulation of the CNS cytokine 
network by SHP-1 following deafferentation. Lack of SHP-1 results in altered expression 
of cytokines in the mouse hindbrain before and after injury, with reduced levels of the 
anti-inflammatory cytokines IL-4 and IL-10 in combination with elevated levels of the 
pro-inflammatory cytokine IL-ip. This cytokine profile may contribute to the excessive 
activation of me/me microglia that is observed following deafferentation.
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CHAPTER THREE
Lipopolysaccharide-activated SHP-1 deficient motheaten microglia release 
increased nitric oxide, TNF-a and IL-ip
Abstract
Accumulating evidence suggests a deleterious role for activated microglia in 
facilitating neuronal death by producing neurocytotoxic substances during injury, 
infection or neurodegenerative diseases. Following cochlear ablation, abnormal 
microglial activation accompanied by increased neuronal loss within the auditory 
brainstem occurs in motheaten (me/me) mice deficient in the protein tyrosine phosphatase 
SHP-1. To determine whether abnormally activated microglia contribute to neuronal 
death in me/me mice, primary microglial cultures from me/me and wild-type mouse 
cortices were stimulated by the bacterial endotoxin lipopolysaccharide (LPS) to evaluate 
the secretion of the neurotoxic mediators nitric oxide (NO), tumor necrosis factor-a 
(TNF-a) and interleukin-ip (IL-ip). Me/me microglia release significantly greater 
amounts of all three mediators compared to wild-type microglia. However, the increased 
release of these compounds in microglia lacking SHP-1 does not appear to occur through 
activation of extracellular signal-regulated kinase (ERK) or p38 kinase subgroups of 
mitogen-activated protein (MAP) kinases. These results suggest that abnormal microglial 
activation can be detrimental to neurons that are already weakened by deafferentation and 
can thus potentiate neurodegeneration in the me/me brainstem. Our data also indicates 
that SHP-1 is engaged in signaling pathways in LPS-activated microglia but not through 
regulation of the ERK and p38 MAP kinases.
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1. Introduction
Microglia are considered to be the important immune effector cells residing in the 
central nervous system (CNS). They serve the role of immune surveillance of damaged 
tissue and become activated in a broad range of CNS disorders, from acute injuries like 
ischemia (Gehrmann et al., 1992; Gehrmann et al., 1995) to chronic neurodegenerative 
conditions such as Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis 
(Kreutzberg, 1996; Nelson et al., 2002; Liu and Hong, 2003). Increasing evidence, 
however, has indicated that microglia can become hyperactivated during injury or 
disease, and can be contributors to secondary damage following CNS injury (Dickson et 
al., 1993; Kalla et al., 2001; Eyupoglu et al., 2003). Activated microglia (Medana et al., 
1997) can secrete a host of soluble factors that are neurotoxic, including reactive oxygen 
species (ROS), nitric oxide (NO), proteinase, glutamate, and inflammatory cytokines 
such as tumor necrosis factor-alpha (TNF-a), which in turn, can exacerbate the 
degeneration of neurons (Barger and Basile, 2001; Liu and Hong, 2003). In addition, the 
bacterial endotoxin lipopolysaccharide (LPS) is a potent activator of microglial cells in 
vitro and the release of NO and TNF-a from LPS-stimulated microglia has been 
demonstrated to be regulated by extracellular signal-regulated kinase (ERK) and p38 
kinase subgroups of mitogen-activated protein (MAP) kinases (Bhat et al., 1998).
However, little is known regarding the role of microglial activation during 
neuronal death induced by deafferentation. We have previously shown that following 
deafferentation of the auditory brainstem, abnormal microglial activation accompanied by 
an increase in neuronal death occurs in motheaten (me/me) mice deficient in the protein
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tyrosine phosphatase SHP-1 (Zhao and Lurie, submitted). While cochlear ablation in 
mice has been shown to result in loss of neurons within the auditory nucleus of the 
brainstem during a limited early stage of postnatal development known as the “critical 
period” (Mostafapour et al., 2000), most of the studies examining the underlying 
physiological machinery that controls whether neurons survive or die following afferent 
removal have focused on the intrinsic properties of neurons (Mostafapour et al., 2000; 
Mostafapour et al., 2002). But glial cells might also participate in this process. Our 
demonstration of a direct correlation between an extended critical period of neuronal loss 
and abnormal microglial activation after unilateral cochlear ablation in mice lacking 
SHP-1 suggests that microglia may play a role in defining the fate of neurons following 
deafferentation. The current in vitro study is designed to examine whether activated 
SHP-1 deficient microglia secrete higher levels of neurotoxic substances NO, TNF-a and 
IL-ip than wild-type.
SHP-1 is a cytoplasmic phosphatase that acts to dephosphorylate a variety of 
intercellular signaling molecules on tyrosine residues. It is expressed predominantly in 
hematopoietic cells (Yi et al., 1992; Shultz et al., 1993) and SHP-1 deficient me/me mice 
display severe hematopoietic abnormalities and immunodeficiencies (Shultz and Green, 
1976). In the CNS, SHP-1 has been implicated in the negative regulation of proliferation 
and differentiation of glial cells after injury (Lurie et al., 2000; Massa et al., 2000). It 
remains to be elucidated whether SHP-1 functions to negatively modulate the production 
of neurotoxic factors by activated microglia, and if so, whether SHP-1 provides this 
negative regulation via the ERK and p38 MAP kinase signaling cascades.
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In the present study, primary microglial cell cultures isolated from wild-type and 
me/me neonatal (P2) mouse cortices were stimulated with LPS, and the secretion of NO, 
TNF-a and IL-ip from activated microglia compared between the two genotypes. The 
phosphorylation state of ERK and p38 MAP kinases induced by LPS activation in the 
SHP-1 deficient microglia was also examined. Our results demonstrate that LPS- 
activated me/me microglia release significantly greater amounts of the neurotoxic 
substances NO, TNF-a and IL-ip compared to wild-type, but this increase does not 
appear to occur through regulation of ERK or p38 MAP kinases. The increased release 
of these neurotoxic substances by me/me microglia may contribute to the increased 
neuronal death observed within the auditory brainstem.
2. Materials and methods
2.3. Animals
The wild-type (+/+) and mutant me/me neonatal mice used for the primary 
microglial cultures were propagated by mating heterozygous +/me mice on a 
C3HeB/FeJLe background obtained from The Jackson Laboratory (Bar Harbor, ME). 
Mice were maintained in the University of Montana Laboratory Animal Resources 
facilities. All animal procedures were in strict accordance with the NIH Guide for the 
Care and Use o f Laboratory Animals and were approved by the University of Montana 
Institutional Animal Care and Use Committee.
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2.2. Mouse Genotyping
Polymerase chain reaction (PCR) amplification of a 426-bp fragment, which 
encompasses the site of the me/me mutation, was utilized to genotype the mice as 
previously described (Zhao and Lurie, submitted). The PCR reaction was carried out 
using forward (5'-CGCTGCTGCTCATGTATCTC-3') and reverse (5'- 
GCCTACAGAGGGAAGAGGCT-3') primers (Operon Technologies, Alameda, CA) and 
the PCR Master Mix (Promega Corporation, Madison, WI). Briefly, 2-3 mm tail samples 
were digested in 100 mM NaOH at 65°C for 3 hours. Digestion was terminated by 
adding 0.75 M Tris-HCl (pH 7.5) prior to centrifugation. DNA was subjected to 35 
cycles consisting of: 30 seconds at 95°C, 1 minute at 56°C, and 1 minute at 72°C. The 
amplified PCR products were digested for 1 hour with Taq I enzyme (New England 
BioLabs, Beverly, MA) at 65 °C and separated by 1.2% agarose gel electrophoresis at 120 
V for 100 minutes. PCR products were stained with ethidium bromide and visualized by 
UV light.
2.3. Primary microglial cultures
Primary microglial cultures were prepared from the cortex of neonatal mice (n = 
2-10 per culture) as previously described by Suo (2002) with some modifications. In 
brief, postnatal day 2 (P2) wild-type and me/me mice were sacrificed by decapitation and 
the cerebral cortices were dissected in Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with F12 containing 15 mM HEPES (Gibco BRL) media mixed with 1%
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antibiotic-antimycotic mixture Penicillin-Streptomycin-FUNGIZONE (PSF, Gibco 
BRL), and meninges and blood vessels were removed. Cortices were then minced with a 
sterile pipet tip and the tissue was dissociated in 0.25% trypsin with 1 mM EDTA (Gibco 
BRL) for 30 minutes at room temperature. Dissociation was terminated by adding an 
equal volume of growth media [DMEM/F12 medium containing 10% heat-inactivated 
Fetal Bovine Serum (FBS, Gibco BRL) and 1% PSF], and dissociated cells were 
triturated to obtain a single-cell suspension. Cells were pelleted by centrifugation at 210 
x g for 5 minutes and washed one more time with fresh growth media. Cells were finally 
seeded at a density of 1 cortex per flask in 75 cm2 T-flasks pre-coated with 0.01 mg/ml of 
poly-L (or D)-lysine (Sigma) overnight. Cells were incubated at 37°C in a humidified 
atmosphere of 5% CO2 in air, and growth media was replaced every third day and to 
generate mixed glial cultures.
By 12 days in vitro (DIV), microglia that were loosely attached to the top of the 
mixed glial monolayer were harvested by shaking on a gyratory shaker at 275 rpm for 45 
minutes. Collected supernatants containing detached microglia were centrifuged at 860 x 
g for 5 minutes, and cells were re-suspended and plated in DMEM/F12 medium 
containing 10% FBS and 1% PSF, either in 12-well culture plates at a density of 4.5 x 
105 cells/well (for measuring secreted compounds) or in 30 mm culture dishes at a 
density of 2.0 x 106 cells/dish (for Western blotting analyses). Non-adherent substances 
were removed 30 minutes later by changing with fresh media.
Purity of microglial cultures was assessed using fluorescence 
immunocytochemistiy by staining cells seeded on poly-L-lysine-coated coverslips (in 12- 
well culture plates) with antibodies against glial fibrillary acidic protein (GFAP; astrocyte
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marker) or F4/80 (microglial marker). This procedure produced pure primary microglial 
cultures with > 95% of microglia (data not shown).
2.4. LPS treatment o f microglia
The endotoxin lipopolysaccharide (LPS) from Salmonella typhimurium was 
obtained from Sigma and the lyophilized product was reconstituted in growth media. 
Cultures of microglia growing in 12-well culture plates were activated by exposure to 
LPS at 1 pg/ml for 1, 9,18,24, or 48 hours and then assessed for NO, TNF-a, and IL-ip. 
Microglial cells growing in 30 mm culture dishes were stimulated by LPS at 1 pg/ml for 
30 minutes and western blots used to assess the phosphorylation state ofERK and p38 
MAPKs. Media with or without LPS treatment was collected, aliquoted, and stored at 
-80°C until use.
2.5. Measurement o f nitric oxide generation
NO production in the microglial culture supernatants was determined by Griess 
reaction using the Nitrate/Nitrite Colorimetric Assay kit according to the manufacturer’s 
instructions (Cayman Chemical, Ann Arbor, MI). Nitrite, the stable derivative of NO in 
the media, was measured. Briefly, 100 pi of the media were mixed with an equal volume 
of 1:1 mixture of sulfanilamide and N-( 1 -Naphthyl)ethylenediamine in 96-well plates. 
Nitrite contents were converted into a colored azo compound that was measured using the 
colorimetric method by reading the absorbance at 540 nm. A nitrite standard curve was 
generated using the nitrite standard reagent provided in the kit.
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2.6. Measurement o f TNF- a  and IL - l f  release
TNF-a and IL-ip released by microglia with or without LPS activation was 
measured using the respective mouse cytokine ELISA kit according to the manufacturer’s 
instructions (BD Pharmingen, San Diego, CA). Microglial supernatants were added to 
Nunc-Immuno™ Maxisorp™ 96-well plates (VWR International) coated with anti­
mouse TNF-a or IL-1(3 monoclonal antibodies. Cytokines were detected by treating the 
plates with respective biotinylated mouse monoclonal antibodies with avidin-horseradish 
peroxidase conjugate. Enzyme substrate solution (BD Pharmingen) containing 
tetramethylbenzidine (TMB) was added to generate a color product and the reactions 
were terminated by adding stop solution (1 M H 3 P O 4 ) immediately before the absorbance 
was read at 450 nm. A recombinant mouse antibody specific to TNF-a or IL-lp included 
in the kit was utilized to produce a standard curve and included in each assay.
2.7. Cell protein isolation
Microglial cells were washed with ice-cold PBS (Gibco BRL), then either 
modified RIPA buffer (Basu et al., 2002) containing a final concentration of 1% Triton 
X-100, 10 mM Tris-HCl, pH 8.0,150 mM NaCl, 0.5% NP-40,1 mM EDTA, 40 pg/ml 
PMSF, 2 pg/ml aprotinin, and 2 pg/ml leupeptin (for using to normalize microglial 
secretions), or lx Cell Lysis Buffer (Cell Signaling Technology, Beverly, MA) 
supplemented with 1 mM PMSF (for Western blot analyses) was added to lyse the cells.
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Cells were immediately scraped off the plates or dishes and sonicated for 15 seconds to 
shear DNA and reduce viscosity. The lysates were incubated on ice for 30 minutes prior 
to centrifugation at 10,000 x g for 10 minutes at 4°C. Protein lysates were aliquoted and 
stored at -80°C until needed. Total protein concentrations in these supernatants were 
analyzed using the BCA Protein Assay Reagent (Pierce, Rockford, IL).
2.8. Western Blot Analysis
Western blot analysis was performed for ERK and p38 MAPK activation using 
PhosphoPlus p44/42 MAP Kinase (Thr202/Tyr204) (ERK 1/2) and PhosphoPlus p38 
MAP Kinase (Thrl80/Tyrl82) Antibody Kits (Cell Signaling Technology) according to 
the manufacturer’s instructions with some modifications. Ten pg of protein extracts from 
microglial cell preparations were denatured by boiling for 5 minutes in Laemmli buffer 
containing 5% 2-mercaptoethanol (2-ME), separated on 10% precast polyacrylamide gels 
(Cambrex Bio Science Rockland, Inc., Rockland, ME), electrophoresed, and transferred 
onto Hybond-P polyvinylidene difluoride (PVDF) membranes (Amersham Pharmacia 
Biotech Ltd., Little Chalfont, England). The membranes were blocked for 1 hour at room 
temperature with 5% dry milk in 20 mM Tris base containing 137 mM NaCl and 0.1% 
Tween 20 (TBST, pH 7.6) and incubated overnight at 4°C with primary antibodies 
(1:1000; phospho-p44/p42 MAP kinase antibody or phospho-p38 MAP kinase antibody). 
After extensive washing with TBST, the membranes were incubated for 1 horn- at room 
temperature with horseradish peroxidase (HRP)-conjugated secondary anti-rabbit 
antibody (1:2000), followed by development with LumiGLO chemiluminescent reagent
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provided in the kit, and the blots were visualized using the VersaDoc 3000 imaging 
system (Bio-Rad) using the Quantity One software. To normalize the phosphorylation 
results, membranes were processed in stripping buffer containing 62.5 mM Tris base, 2% 
SDS and 100 mM 2-ME, pH 6.8 at 65°C for 30 minutes and reprobed with antibodies 
specific for total p44/42 or p38 MAP kinase, respectively.
2.9. Statistical analyses
Data were produced from three or more independent microglial culture 
preparations. Differences in NO, TNF-a and IL-ip production between groups were 
compared by two-way ANOVA. Phosphorylation of ERK and p38 MAP kinases within 
microglia was evaluated using ANOVA impaired t-test. The data are presented as the 
mean ± standard error of the mean (SEM), p < 0.05 was considered significant.
3. Results
3.1. Increased NO release from LPS-activated me/me microglia
Nitric oxide has been demonstrated to be released by cultured murine microglia 
and substantially involved in the mechanisms of neurodegeneration (Chao et al., 1992; 
Peterson et al., 1994). As demonstrated by Figure 13, LPS stimulation induces 
significantly more NO production from me/me microglia compared to wild-type 
microglia at all times (p < 0.001). It should be noted that, although me/me microglia
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Figure 13. Nitric oxide release from wild-type vs. me/me microglia
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Figure 13. LPS induced NO release from cultured wild-type vs. me/me microglia. 
Microglia of each genotype were treated with 1 pg/ml of LPS for the indicated time 
periods. Media was applied without LPS exposure at 1 and 48 hr, the two control time 
points. NO release was determined by the Griess reaction, and normalized to the total 
protein concentrations of the cultured microglia. Results are taken from three 
independent cultures per time point. Significant difference between the two genotypes 
for the entire time course of NO release is analyzed by two-way ANOVA (p < 0.001). 
Data are expressed as the mean + SEM (standard error of the mean).
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secrete considerably more NO compared to wild-type, the time course of release is 
similar between the two genotypes, with the upregulation of NO production starting at 18 
hrs and peaking at 48 hrs following LPS exposure.
3.2. Enhanced TNF-a production from LPS-activated me/me microglia
The pro-inflammatory cytokine TNF-a is another potent neurotoxic mediator that 
could be produced by microglial cells in response to injury or stimuli such as LPS 
(Nicholas et al., 2001; Sriram et al., 2002; Eskes et al., 2003). Therefore, the secretion of 
TNF-a from LPS-activated me/me and wild-type microglia was determined at 1, 9,18, 
24, and 48 hrs of exposure (Fig. 14). Both wild-type and me/me mouse microglia release 
TNF-a into the media soon after stimulation by LPS (1 hr) and continue through 48 hr, 
the last measured time point. However, LPS treatment results in significant increases in 
the amount of TNF-a production by me/me microglia compared to wild-type for the 
whole time course of activation (p < 0.0001). This is particularly obvious, from 9 
through 48 hrs of LPS exposure with peak secretion occurring at 9 hr (70 ng/mg of cell 
protein). In contrast, maximal TNF-a release by wild-type microglia is also observed at 
9 hrs of LPS treatment, but is approximately 30 ng/mg of cell protein (Fig. 14). TNF-a 
release diminishes in both wild-type and me/me microglia by 48 hr post-activation.
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Figure 14. TNF-a production induced by LPS activation of cultured wild-type vs. 
me/me microglia. Microglia of each genotype were treated with 1 jj,g/ml of LPS for the 
indicated time periods. At two control time points, 1 and 48 hr, media was applied 
without LPS exposure. TNF-a production was determined by ELISA assay, and 
normalized to the total protein concentrations of the cultured microglia. Results are taken 
from three independent cultures per time point. Significant difference between the two 
genotypes for the entire time course of TNF-a release is analyzed by two-way ANOVA 
(p < 0.0001). Data are expressed as the mean ± SEM (standard error of the mean).
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3.3. Elevated levels ofIL-1 fi secretion from LPS-activated me/me microglia
Activated microglial cells also release the cytokine IL-1 {3 and increasing evidence 
has suggested a detrimental function for this pro-inflammatory cytokine following CNS 
injury and in several inflammatory neurological disorders (Basu et al., 2002; Griffin and 
Mrak, 2002; Ma et al., 2002; Pinteaux et al., 2002). Figure 15 demonstrates that 
activated microglia do produce IL-ip with detectable levels observed from both wild- 
type and me/me microglia at 9,18,24 and 48 hours of LPS stimulation. Notably, our 
data show me/me microglia release significantly higher levels of IL-1P compared to wild- 
type following 18-48 hrs of LPS stimulation (Fig. 15, p < 0.01). Again, the pattern of IL- 
1 p secretion between me/me and wild-type mouse microglia is similar, with peak 
expression occurring at 24 hours of LPS activation.
3.4 Increased production o f NO, TNF-a and IL-1 J3from LPS-activated me/me microglia 
does not occur through activation o f ERK or p38 MAP kinases
Activation of the ERK and p38 kinase subgroups of MAP kinase has been shown 
to be associated with the production of NO and TNF-a from LPS-activated cultured 
microglia (Bhat et al., 1998). In order to evaluate whether the loss of SHP-1 results in 
increased activation of ERK or p38 following LPS stimulation, the phosphorylation 
(activation) state of ERK 1/2 and p38 MAPKs was evaluated in wild-type and me/me 
microglia.
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Figure 15. IL-ip secretion from wild-type vs. me/me microglia
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Figure 15. IL-1 (3 secretion induced by LPS activation of cultured wild-type vs. me/me 
microglia. Microglia of each genotype were treated with or without 1 pg/ml of LPS for 
1,9, 18, 24, and 48 hrs. IL-ip levels were determined by ELISA assay, and normalized 
to the total protein concentrations of the cultured microglia. Only the time periods with 
detectable IL-1 (3 production are shown. Results are taken from three independent 
cultures per time point. Significant difference between the two genotypes for the entire 
time course of IL-113 release is analyzed by two-way ANOVA (p < 0.01). Data are mean 
± SEM (standard error of the mean).
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As seen in Figure 16, LPS potentiates strong phosphorylation of ERK 1 and 2 
(p44 and p42) 30 min after stimulation in both genotypes of microglia as demonstrated by 
Western blot (Fig. 16A). Densitometric analysis of the double bands of ERK reveals 
that there is statistically significant (p < 0.01) induction of ERK phosphorylation after 
LPS treatment in wild-type as well as in me/me mouse microglial cells (Fig. 16B). 
However, lack of SHP-1 in me/me microglia fails to result in an up-regulation of ERK 
phosphorylation compared to wild-type.
Similarly, phosphorylation of p38 MAP kinase is evident in both wild-type and 
me/me microglia primed by LPS exposure for 30 minutes as shown by Figure 17A. 
Densitometric analysis demonstrates significant (p < 0.01) phosphorylation of p38 
MAPK by LPS stimulation in both cultured wild-type and me/me microglia (Fig. 17B). 
However, this LPS-induced phosphorylation of p38 kinase does not appear to be affected 
by loss of SHP-1, as there are no significant differences in phosphorylation of p38 kinase 
between the two genotypes (Fig. 17B). Thus, the increased production of TNF-a and NO 
from activated me/me microglia does not appear to occur via activation of ERK and/or 
p38 MAP kinases.
4. Discussion
The current study demonstrates that LPS-activated me/me microglia secrete 
increased amounts of the cytotoxic substances NO, TNF-a and IL-ip compared to wild- 
type microglia. These results confirm that, in vitro, activated me/me microglia are
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Figure 16. LPS-induced ERK phosphorylation in microglia
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Figure 16. LPS activation induces similar amounts of ERK phosphorylation in cultured 
wild-type and me/me microglia. A: Wild-type and me/me microglial cells growing in 30 
mm culture dishes (2 x 106 cells/dish) were treated with or without LPS (1 pg/ml) for 30 
minutes and lysed in Cell Lysis Buffer for Western blot analysis of ERK 1/2 (p44/42) 
phosphorylation as described in Materials and Methods. Blots were incubated with 
antibody to phospho-p44/42, stripped and reprobed with antibody to total p44/42 to 
verify equal protein loading. Note that LPS activation induces similar amounts of 
phosphoiylated ERK in the two genotypes. B: Quantification of ERK phosphorylation 
with densitometric analysis of Western blot using Quantity One software. Values are 
obtained as a ratio of the density of phosphor-p44/42 to the density of total p44/42. Data 
are expressed as the mean ± SEM from three to six independent culture preparations. 
Asterisks indicate significant differences compared to untreated groups within each 
genotype (**p < 0.01).
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Figure 17. LPS-induced p38 MAPK phosphorylation in microglia
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Figure 17. LPS-activated p38 MAPK phosphorylation appears similar in cultured wild- 
type and me/me microglia. A: Wild-type and me/me microglial cells growing in 30 mm 
culture dishes (2 x 106 cells/dish) were treated with LPS (1 pg/ml) for 30 minutes, and 
untreated control and treated cells were lysed in Cell Lysis Buffer for Western blot 
analysis of p38 phosphorylation as described in Materials and Methods. Blots were 
incubated with an antibody to phospho-p38 MAPK, stripped and reprobed with an 
antibody to total p38 MAPK to verify equal protein loading. Note that LPS activation 
results in a similar induction of phosphorylated p38 MAPK in both genotypes. B: 
Quantification of p38 MAPK phosphorylation with densitometric analysis of the Western 
blot using Quantity One software. Values are obtained as a ratio of the density of 
phosphor-p38 to the density of total p38, and the data are expressed as the mean ± SEM 
from three to six independent culture preparations (n = 3-6 per culture). Asterisks 
indicate significant differences compared to untreated groups within each genotype (**p 
< 0.01).
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potentially more neurotoxic than wild-type microglia and might explain our previous in 
vivo findings where excessive microglial activation is correlated with increased neuronal 
death within the auditory brainstem of me/me mice following cochlear ablation (Zhao and 
Lurie, submitted). In addition, LPS activation was found to cause a similar 
phosphorylation of ERK and p38 MAP kinases within wild-type and me/me microglia. 
This suggests that the increased production of NO, TNF-a and IL-P by activated me/me 
microglia is regulated either through a pathway other than the ERK and p38 kinase 
signaling cascades, or via signaling molecules down-stream of these two MAPKs.
4.1. SHP-1 and microglial activation
SHP-1 has been implicated as a negative regulator in cell growth, proliferation 
and/or differentiation in various types of cells, including T lymphocytes (Saxena et al., 
1998), myeloid cells (Dong et al., 1999), astrocytes (Lurie et al., 2000; Wishcamper et al., 
2003), oligodendrocytes (Massa et al., 2000), and epithelial cells (Duchesne et al., 2003). 
In the present study, we demonstrate a negative role for SHP-1 in mediating mouse 
microglial activation and differentiation, as revealed by increased NO, TNF-a and IL-lp 
release from LPS-activated me/me microglia compared to wild-type microglia. The 
production of NO and TNF-a (or the expression of mRNAs encoding these substances) 
by LPS or IFN-y- stimulated microglia is a hallmark of microglial activation in vitro 
(Chao et al., 1992; Gazzinelli et al., 1993; Paris et al., 2000). The present finding that 
activated me/me microglia secrete substantially more NO, TNF-a and IL-ip in a 9-48 hr 
period of LPS activation, indicates a non-transient negative regulationby SHP-1 in
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modulatingjmicroglial activation and production of these cytotoxic mediators. It should 
also be noted that me/me microglia in vitro appear to grow at a faster rate than wild-type 
cells (Zhao and Lurie, personal observation), suggesting a negative role for SHP-1 in 
controlling microglial proliferation. Because microglia are macrophage-like cells, this 
observation is consistent with the finding that me/me peripheral macrophages have a very 
high proliferative capacity in vitro (Miyamoto et al., 1998).
A number of studies have elucidated the function of SHP-1 in controlling 
cytokine signaling and the cellular immune response in various systems. The 
involvement of SHP-1 in regulating the cytokine initiated JAK/STAT (Janus 
kinase/signal transducers and activators of transcription) and transcription factor NF-kB 
(nuclear factor-kappa B) signaling pathways has been demonstrated in macrophages and 
astrocytes, respectively (David et al., 1995; Haque et al., 1998; Massa and Wu, 1998). 
However, the role of SHP-1 in modulating cytokine production from specific CNS glial 
cell types and the resultant consequence of neuron-glia crosstalk during brain injury is 
not well understood. The present study is the first to describe a role for SHP-1 in the 
negative regulation of TNF-a, and IL-1 (3, as well as the free radical NO, production from 
activated microglial cells.
4.2. Activated microglia secrete neurotoxic substances
Secretion of NO, TNF-a and IL-lp from activated microglia has been widely 
accepted to be cytotoxic, triggering neuronal death and/or degeneration (Banati et al., 
1993; Hirsch et al., 2003; Liu and Hong, 2003). NO generated from activated microglia
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has been shown to mediate neurodegeneration by inhibiting neuronal respiration and 
causing glutamate release, resulting in excitotoxicity (Bal-Price and Brown, 2001). The 
pro-inflammatory cytokines TNF-a and IL-ip that are released by activated microglia are 
thought to stimulate NO production in glial cells, and may exert a more direct deleterious 
effect on neurons by activating receptors that contain the intracytoplasmic death domains 
involved in apoptosis (Hirsch et al., 2003). It has also been demonstrated that TNF-a and 
IL-1 (3 can work synergistically to induce degeneration of cortical neurons (Chao et al., 
1995; Jeohn et al., 1998). The present study confirms that activated me/me microglia are 
potentially more toxic to neurons than activated wild-type microglia, particularly to those 
neurons that are already vulnerable due to afferent deprivation.
4.3. SHP-1 and ERK andp38 MAPKs
Two of the three common MAPKs, ERK and p38 kinases, have been 
demonstrated to be activated by bacterial LPS or the non-replicating adenovirus vectors 
(AdV) in brain microglia and are implicated as key signaling pathways in regulating 
microglial expression of iNOS and TNF-a, and NO production (Bhat et al., 1998; Bhat 
and Fan, 2002). Additional studies have documented the participation of only p38 
MAPK in mediating iNOS gene expression in either LPS- or hypoxia-induced activated 
microglia (Han et al., 2002; Park et al., 2002) while ERK activation does not appear to be 
a required function of LPS-mediated signaling events in macrophage/microglial cells 
(Watters et al., 2002). Nevertheless, the present study shows that both ERK and p38 
MAP kinases are activated (as determined by induced phosphorylation) following LPS
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activation in both wild-type and me/me microglia. Interestingly, although activated 
me/me microglia produce more NO, TNF-a and IL-1 (3, there is no change in the 
activation of ERK or p38 MAP kinase in these cells compared to wild-type. This is 
intriguing because evidence has shown that SHP-1 is able to inhibit ERK activity in 
angiotensin II type 2 receptor (AT2)-induced apoptosis and AT2- mediated EGFR 
(epidermal growth factor receptor) signaling (Lehtonen et al., 1999; Shibasaki et al., 
2001). In contrast, loss of SHP-1 results in decreased phosphorylation of p38 kinase 
from spleen cells of me/me mice in response to gamma-irradiation-induced stress (Hsu et 
al., 2001). However, our finding that loss of SHP-1 does not affect the activation of both 
ERK and p38 kinases in activated microglial cells suggests that microglial secretion of 
NO, TNF-a, and IL-1 p is not occurring exclusively through ERK or p38 MAP kinase 
signaling pathways. These results are consistent with those of You et al. (2001), who 
found that SHP-2, an analogue of SHP-1, does not work through the three types of 
MAPK pathways in mediating IL- 1/TNF-induced IL-6 synthesis but instead, modulates 
the NF-kappa B pathway. Accordingly, our data suggests that over-production of NO, 
TNF-a and IL-ip in activated me/me microglia is either independent of the ERK and p38 
MAP kinase pathways or that SHP-1 acts as a downstream regulator in MAPK signaling 
pathways. Future studies will address this issue.
In conclusion, the current study demonstrates that me/me microglia lacking SHP-1 
release significantly increased amounts of the neurotoxic substances NO, TNF-a and IL- 
ip compared to wild-type microglia in response to LPS stimulation. In addition, LPS- 
induced activation of ERK and p38 is not affected by the absence of SHP-1, indicating 
that the increased secretion of these neurotoxins occurs via regulation of alternative
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signaling pathways or downstream effectors of the MAP kinase pathways. Our findings 
add additional support to our previous hypothesis that abnormally activated me/me 
microglia may contribute to the increased neuronal death observed within the 
deafferentated auditory brainstem.
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CONCLUSIONS
The current studies investigate the role of the protein tyrosine phosphatase SHP-1 
in the cellular mechanisms of deafferentation-induced neuronal death in the murine 
auditory brainstem using mutant mice lacking active SHP-1 protein. Specifically, the 
function of activated microglia is explored as SHP-1 has been implicated in glial 
proliferation and differentiation in the CNS.
Termination of auditory afferent input activity by cochlear ablation results in an 
extended critical period of neuron loss in the me/me AVCN beyond PI 4 but not P21 
compared to wild-type littermates, suggesting a requirement of SHP-1 in maintaining 
survival of post-injury neurons, especially those that may still be vulnerable to 
deafferentation injury. Specifically, an exaggerated microglial but not astrocyte 
activation corresponding with a significantly increased loss of AVCN neurons is seen in 
P14 me/me mice 4 days following unilateral cochlear ablation. In contrast, 
miCroglial/astrocyte activation and neuron loss at P5 or P21 is indistinguishable between 
wild-type and me/me mice. These results suggest that abnormally activated me/me 
microglia are a factor contributing to neuronal death following deafferentation atP14 as 
activated microglia have been demonstrated to be capable of releasing neurotoxic 
substances. This again suggests a role for SHP-1 in negatively regulating glial activation.
These studies also show that it is the magnitude, not the time course, of microglial 
activation that is altered in me/me mice. This lends more support to the hypothesis that 
there is a correlation between the greater magnitude of microglial activation and the 
increased neuronal death in AVCN of the P14 me/me mice. It should also be noted that
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there is a normal auditory startle response and normal AVCN synaptophysin 
immunoreactivity in P14 me/me mice, confirming that the auditory system of me/me mice 
is fully developed at P14 and that neuronal loss is not due to delayed development.
However, microglial activation due to lack of SHP-1 appears to be one of many 
coexisting contributors to AVCN neuronal degeneration following deafferentation of the 
auditory system. Other factors like the maturation of synapses projecting from the 
peripheral auditory eighth nerve to AVCN neurons may also play a key role in 
determining the fate of neurons following afferent injury. In support of this hypothesis, 
both wild-type and me/me mice show a prominent amount of neuronal loss and activated 
microglia at P5, suggesting that activated microglia are capable of inducing neuronal 
death when synaptic connections are very immature. At PI4, me/me but not wild-type 
mice display significantly more neuronal death and microglial activation, indicating that 
exacerbated microglial activation can kill AVCN neurons when synaptic maturation has 
just occurred and neuronal susceptibility to deafferentation may still be high. Finally, 
neuronal loss in me/me mutants does not take place at P21, suggesting that activated 
microglia are no longer able to induce neuronal death because functional synaptic 
connections are mature and confer some protection onto AVCN neurons.
The cytokine environment also appears to play a role in the response of the me/me 
brain to deafferentation. Brain inflammation in response to trauma or injury is largely 
modulated by the immunoregulating function of microglial cells, and SHP-1 belongs to 
one of the three major families of the negative regulators of the JAK/STAT proteins 
involved in many cytokine signaling pathways (Hilton, 1999; Kile et al., 2001). The 
present studies found that SHP-1 deficiency results in reduced levels of the anti-
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inflammatory cytokine IL-10 and elevated levels of the pro-inflammatory cytokine IL-ip 
in the intact me/me mouse hindbrain compared to wild-type, setting the stage for an 
inflammatory response once injured. Me/me mutants continue to demonstrate decreases 
in IL-4 and IL-10 (anti-inflammatory) and increases in IL-lp (pro-inflammatory) at 1 day 
after cochlear ablation. Although the cytokine induction appears to be delayed in me/me 
mice, the combination of early down-regulation of anti-inflammatory cytokines and up- 
regulation of pro-inflammatory cytokines could provide a sufficiently aberrant cytokine 
environment that favors inflammation and microglial activation in me/me mice in 
response to deafferentation.
Once activated, me/me microglia release more neurotoxic substances than wild- 
type. Me/me microglia in culture secrete increased amounts of NO, TNF-a and IL-ip, all 
of which could contribute to the increased neuronal death observed in P14 mice. 
Interestingly, the signaling molecules ERK and p38 MAP kinases that have been shown 
to be associated with the activation of microglia fail to show a difference in 
phosphorylation (activation) between wild-type and me/me microglial cells with LPS 
stimulation. This suggests that SHP-1 regulates a different signaling cascade leading to 
increased microglial activation in me/me mice, or that alternatively, the modulation of 
SHP-1 is employed down-stream of the two MAPKs.
In summary, the current studies demonstrate that loss of SHP-1 results in an 
altered cytokine environment that favors microglial activation in the uninjured mouse 
hindbrain. Following cochlear ablation, there is a decrease in anti-inflammatory 
cytokines and an increase in the pro-inflammatory cytokine IL-lp in P14 me/me mice 
compared to wild-type. This in turn, results in upregulated microglial activation in the
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SHP-1 deficient mice. The elevated secretion of neurotoxic substances from these 
increased numbers of activated microglial cells could then lead to greater neuronal death 
within AVCN.
These studies are summarized below.
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